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ABSTRACT
Although it is unclear which cellular factor(s) is responsible for the genetic
instability associated with initiating and sustaining cell transformation, it is known that
most, if not all, cancers have mutations that inactivate the Rb-mediated growth control
pathway. We show here that acute inactivation ofRb by RNA interference or expression
of the E7 viral oncoprotein from human papilomavirus (HPV), and the resultant
deregulation of one E2F family member, E2Fl , leads to DNA double strand break (DSB)
accumulation. These DSBs occur independent of apoptosis induction, and activation of
ATM, NBSl , p53 , or MAD2 , and generation of reactive oxygen species (ROS).
Although ROS accumulation is associated with DSBs generated from the mis-
expression of another nuclear oncoprotein, c-MYC, we find that E2Fl does not contrbute
to c-MYC associated DSBs, indicating that theDSBs associated with these oncoproteins
arise through distinct pathways. However, we find that small changes in E2F 1 levels by
inhibition of c-MYC trans activated microRNAs known to limit E2Fl protein expression
lead to DSB accumulation. These results suggest that despite the DSBs arising by
different mechanisms , c MYC assists in the regulation ofE2Fl-associated DSBs.
We also find elevated levels of E2F 1- associated DSBs in Rb mutated cancer cell
lines in the absence of an exogenous DSB stimulus. These basal, E2F I-associated DSBs
are substantially lower in Rb wildtype cancer cell lines that have p 16ink4 inactivated or
express HPV E7. However, we show that we can manipulate DSB levels in these cancer
cell lines by modulating Rb and E2Fl activity and suggest that these results may be
extended to breast tumor organ cultJre. Thus Rb status is key to regulating both the
proliferation promoting fuctions associated with E2F and for preventing DNA damage
accumulation if E2Fl becomes deregulated. Taken together, these data suggest that loss
of Rb creates strong selective pressure, via DSB accumulation, for inactivating p53
mutations and that E2Fl might contrbute to the genetic instability associated with
transformation and tumorigenesis.
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CHAPTER I:
INTRODUCTION
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A. Cell Cycle Overview
The process of faithfully replicating the genetic information of a cell and its
subsequent division into two daughter cells is known as the cell cycle. The cell cycle can
be envisioned as alternating cycles of interphase, where the cell grows in size
synthesizes RNA and proteins, and replicates its DNA, and mitosis (M), where the newly
0\)
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replicated cell divides. At times, cells may exit the cell cycle after M and remain
, (:
I;,
i:,
quiescent in a resting phase (G ). Once the cell receives a mitogenic stimulus, cells
r..
reenter the cell cycle at gap phase 1 (G ), a growth phase prior to replication, followed by
entry into synthesis (S), where the DNA of the cell is replicated, succeeded by gap phase
2 (G2), a growth phase preceding cell division in M (Figure 1.1). Progression through the
four stages of the cell cycle is ordered and tightly regulated to ensure that only one round
of DNA replication occurs per cell cycle and that cell division only occurs after
replication is complete. To combat stressors that cells may encounter as they progress
through the cell cycle, such as misaligned chromosomes or damaged DNA, cells elicit
checkpoints that halt cell cycle progression and allow the cell to try and amend thei "
! '
problem. However, if the damage is too severe or if repair is untimely, cells wil either
1;1
undergo apoptosis, which is a programmed cell death, or become senescent, which is a
: ';
state of permanent arrest. Cell cycle arrest and elimination of damaged cells by apoptosis
are extremely important processes to an organism in preventing the transmission of
damaged or incompletely replicated DNA to new daughter cells and thereby acts as a
preventative measure against diseases like cancer.
:'i
i ,
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B. Normal Cell Cycle Progression and Regulation
Regulation by cyclins and cyclin dependent kinases
The stringent regulation of cell cycle progression from one phase into the next
phase is mainly governed by cyclin dependent kinases (cdk). These serine/ threonine
kinases are inactive as monomers and are completely dependent on regulatory subunits
or cyclins, for activation of their kinase activity. Each phase of the cell cycle is associated
with specific cyclin/cdk complexes (Figue 1.1)(256 , 263 , 265 , 287). In early G , when
quiescent cells are stimulated by mitogens, the D-type cyclins (D1 , D2, and D3) are
transcribed and form complexes with their cdk components, cdk4 or cdk6. Later in G
the E-tye cyclins (E1 and E2) are expressed and bind Cdk. This complex remains
active through the G to S phase transition, after which, cyclin E levels are degraded.
Cdk2 continues to regulate cell cycle progression via its interaction with cyclin A, which
is detectable at low levels during late G but is maximized in S and persists until it is
degraded early in M. Although the major cyclin/cdk complex involved in M is cyclin
B/Cdk1 , exit from mitosis requires that cyclin B be degraded by the ubiquitin pathway at
the transition from metaphase to anaphase during M.
Regulation of these cyclin/cdk complexes is accomplished by a variety of
mechanisms (183 , 256, 263 , 265 , 287). First, the synthesis of the cyclin component is
tightly regulated by transcription and protein degradation, thereby regulating the cdks
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Figure 1.1: Temporal expression of the cyclin/cdks during the cell cycle.
The four stages of the cell cycle are depicted, as well as the G resting state.
When cells receive a growth stimulus, they enter the cell cycle in G , replicate
their DNA in S , prepare for division in G , and divide in M. Progression from
one phase into the next phase is tightly regulated by expression of cyclin/cdk
complexes. The complexes that are active during each phase of the cell cycle
are depicted.
because of their dependence on the binding of the cyclin component for their activity.
Additionally, the cdk component of the complex is regulated by covalent modification.
For example, in order to be active, a threonine residue within the " Ioop" of the catalytic
site of the cdk must be phosphorylated by a cdk activating kinase (183). In tu
, a cdk.;
associated phosphatase removes the phosphate from the cdk following destruction of the
cyclin protein. Another layer of regulation is spatial localization (264). One example of
spatial regulation is the coordination of the proteolytic degradation of cyclin D 1. During
GJ, cyclin D 1 accumulates in the nucleus but must be shuttled to the cytoplasm during S
(72 , 73). The kinase responsible for phosphorylating and thereby marking cyclin D1 for
transport to the cytoplasm for degradation, GSK-3f3, remains cytoplasmic during G) and
transports into the nucleus during S (72). Finally, cyclin/cdk complexes are regulated by
a class of proteins known as cyclin dependent kinase inhibitors (CDKi). There are two
broad classes of CDKi proteins, the INK4 and CIP families (256, 263 , 303). The INK4
proteins are largely responsible for governing proliferation signals due to their high
affnity and exclusive binding of cdk4 and cdk6 (250, 297 , 360). Strctual analyses have
shown that INK4 proteins form binary complexes with cdk4 or cdk6 by binding adjacent
to the A TP binding site of the catalytic cleft, causing a conformational change which
causes cyclin D dissociation, thereby facilitating its degradation and limiting G cell
cycle progression (32, 151 , 284). In response to cell stress, the CIP family of CDKi can
bind the active cyclin/cdk complex in that phase of the cell cycle and thereby help elicit a
checkpoint.
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Figure 1.2: Schematic of GI-S phase regulation of the eukaryotic cell cycle.
Maintenance of the cell in is accomplished by the cyclin dependent kinase
inhibitors, p16INK4 and CIPs. When a cell is stimulated to grow, the Rb protein is
hyperphosphorylated by cyclin D/cdk 4 6 and cyc1in E/cdk complexes. As a
consequence, free E2F transactivates the promoters of genes required for S phase.
These events constitute the restriction checkpoint (R) and commit the cell 
another round of replication.
::j:
The Retinoblastoma Family of Proteins
One important checkpoint that occurs during G is the Restriction Point (R),
which is the commitment step for a cell to undergo another round of replication (Figue
2). Prior to proceeding through R, cells are dependent on mitogenic signals for
progressing through G because cyclin D transcription is dependent on the presence of
growth factors (213). However, passage through R renders cells independent of the
presence of growth factors until the next G (213). The events associated with passage
through R are the phosphorylation and inactivation of the retinoblastoma (RB) family of
proteins by the cyclin D/cdk4 6 andcyclin E/cdk2 complexes (25). The mammalian RB
pocket" protein family consists of three members: Rb, p 107 , and p 130 , which maintain
quiescence by repressing the expression of key genes involved in cell cycle transitions
and terminal differentiation by binding those proteins via an LxCxE motif in the C-
terminus (56 , 84, 235). Each of the RB members has a unique expression pattern during
the cell cycle (Figue 1.3A). In quiescent cells and terminally differentiated cells, p130 is
highly expressed (59 , 310). However, when cells are stimulated to proliferate, p130 is
shuttled to the cytoplasm and rapidly degraded in the 26S proteasome (271 , 311 , 325).
Conversely, pI 07 is at very low levels in quiescent cells and terminally differentiated
cells (165, 306) but accumulates when quiescent cells enter the cell cycle and then
remains at a constant level in proliferating cells until cells exit the cell cycle (20
, 184).
On the other hand, Rb is present in quiescent cells and then slightly accumulates in
cycling cells (298). Although protein levels do not dramatically change, the activity ofRb
928
42Y 38%
1139 66% 1068p130 p107
Figure 1.3: Comparison of the three RB family members.
(A) Schematic representations of Rb (red), p130 (blue), and p107 (green). The
overall amino acid similarity is shown. Little similarity is observed in the Nand C
termini of Rb compared to p130 (37% N, none C) or p107 (37% N, 47% C),
although the similarity is high in these regions for p107 and p130 (75% N
, 72%
C). The highest similarity between all three proteins is observed in domain A and
domain B:Rb and p107 (59% A, 63% B), Rb and p130 (57% A, 65% B), p130
and p107 (71 % A, 90% B). There is no appreciable similarity in the spacer region
for Rb with either p107 or p130 , and 57% between p107 and p130. (B) Diagram of
the RB family protein levels during the transition from quiescence to DNA
replication (Adapted from (235)). p130 levels are high in G and decrease with cell
cycle progression. pI 07 levels accumulate through the Gj-S transition. Rb levels
increase slightly in S.
fluctuates during cell cycle During G and early G , RbprogresSIOn.
hypophosphorylated and actively fuctions as a repressor. Once phosphorylated and
inactivated by cyclin/cdk complexes, Rb is maintained in its inactive
hyperphosphorylated state through S and late M (56, 84 234).
Strcturally, there are regions of amino acid similarity between all three RB
members, but it is clear that p 107 and p 130 are more closely related to each other than
either protein is related to Rb (Figure l.3B) (56). Consistent with this observation
, mouse
models indicate that fuctional redundancy exists for p130 and p107. Mice that are
homozygous deficient for both genes die shortly after birth (58), whereas homozygous
deletion of either pI07 or p130 renders viable, normal mice (58, 182). In contrast
homozygous deletion of Rb is embryonic lethal, indicating that neither p130 nor p107 can
compensate for loss ofRb (55 150 179).
The E2F Family a/Transcription Factors
One key set of gene products that the RB proteins negatively regulate is the E2F
family of transcription factors. Traditionally, the perception of these proteins is that they
control the transcription of gene products required for S phase. However, data generated
from microarray and chromatin immunoprecipitation analyses have shown that E2F
proteins actually regulate a diverse set of genes involved in, not only, cell cycle
transitions, but also differentiation, apoptosis, DNA repair, and checkpoint signaling, as
well as some unidentified genes (147, 206 , 225 , 266, 270). To date, there are nine E2F
gene products (Figue 1.4). Because the E2Fs have a broad range of functions, they are
classified as either transcriptional activators or transcriptional repressors. The family
members are fuher divided into four subgroups based on their expression patterns, their
specificity and affnity for binding the different RB members, and whether they
heterodimerize with the DRTF1-polypeptide (DP) transcription factors, an interaction
which enhances DNA binding affnity and the transactivation activity of the heterodimer
(111).
E2F1 (125, 157, 300), E2F2 (148, 185), and E2F3a (185) comprise the
transcriptional activators, and are known to transactivate the promoters of gene products
that are required for DNA replication, like DNA polymerase a, thymidine kinase, and
dihydrofolate reductase (67). The necessary and required role for these proteins in cell
cycle progression from G into S was demonstrated by the observation that mouse
embryo fibroblasts (MEFs) that are deleted for all three genes are defective in S phase
entry (356). Additionally, all three proteins can drve cells into S when overexpressed in
quiescent rodent fibroblasts indicating their potency in cell cycle progression (67, 68
153 , 174, 269, 299 , 340). The activator E2Fs are specifically negatively regulated by the
Rb member of the RB family (125 , 148, 157, 185 , 300), so their activity is derepressed
and induced at the G to S phase transition after Rb is hyperphosphorylated and
inactivated by G cyclin/cdk complexes. Because the E2Fs target their own promoters
proteip.levels accumulate at the G to S transition and in order for cells to exit S , E2F
activity must be down-regulated (175).
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Figure 1.4: Diagrams of the E2F family of transcription factors.
Schematic representations of each of the E2F family members. E2F1 , E2F2, and
E2F3a belong to the activator subclass of the E2F family. The remaining E2F
proteins repress gene expression. E2F3b, E2F4, and E2F5 are RB family binding
proteins. E2F6, E2F7, and E2F8 function as transcriptional repressors in an RB-
independent manner. The Cyclin A binding domain (CA), DNA binding domain(DUD), dimerization domain (DIM), transactivation domain (TA), and
retinoblastoma protein binding domain (RB) are depicted. The amino acid length of
each protein is listed. Diagrams are not drawn to scale.
Unlike , the transcriptional activators, the protein levels of the transcriptional
repressors E2F3b (123 , 188), E2F4 (21 , 107 288), andE2F5 (132 288) are not cell cycle
regulated and remain relatively equivalent in quiescent and cycling cells (66). However
the activity of E2F4 and E2F5 is cell cycle regulated by fluctuating their cellular
localization with the phase of the cell cycle. During /GI, E2F4 and E2F5 are mainly
bound by p130 and these complexes occupy E2F regulated promoters in the nucleus (56
, 84, 235 , 288). However, due to lack of a nuclear localization signal (NLS), E2F4 and
E2F5 may be exported to the cytoplasm during S and it is thought that they are
relocalized to the nucleus following binding p107 orp130 (3, 6, 226, 339). Although
E2F4 has been shown to have slight affnity for binding Rb in some cell contexts (143
220) both E2F4 and E2F5 preferably bind p130 and p107 in most circumstances (21 , 132
338). E2F3b, on the other hand, is regulated by Rb. The E2F3b transcript is encoded from
a unique coding exon in the same genetic locus as E2F3a, resulting in a protein that
differs from E2F3a in its N-terminus but retains the same Rb binding domain (123 , 188).
Additionally, E2F3b retains its NLS and is thought to constitutively repress specific E2F
regulated genes in cycling cells (9, 74).
E2F6 (40, 222, 331) is a transcriptional repressor that mediates repression in an
RB-independent manner because it lacks a transactivation domain and the sequences
necessary for RB binding. Rather, E2F6 acts as a repressor by binding polycomb (PcG)
proteins (241 , 332), which have been shown to be necessary for regulating the
developmental expression patterns of Hox genes (114, 292). Although the exact role of
E2F6 is presently unclear, the observation that E2F6-
/- 
mice have very similar phenotyes
as several mouse models with PcG deficiencies suggests a role in development in the
axial skeleton (316). Additionally, E2F6 may repress E2F targets that are activated at the
/S boundary (105).
The final subgroup of E2F transcriptional repressors includes E2F7 (62 , 70, 199)
and E2F8 (54, 200, 210). Both proteins contain two tandem DNA binding domains
which allow them to bind E2F promoter sequences independently ofDP (54 , 70, 199
200; 210). Consistent with the observation that E2F7 and E2F8 are E2F target genes, they
are cell cycle regulated; however, they do not bind RB proteins (54, 62, 70, 199, 200
210). Ectopic expression of either protein inhibits cell cycle proliferation (54 , 70, 199
200 , 210). A unique feature of E2F7 is its ability to associate with E2F promoters in S
and G , suggesting that it may repress target gene expression at times in the cell cycle
when other E2Fs are inactive (62).
Functional Roles of RB Regulated E2F Activity
E2F was originally discovered as a cellular binding factor at the promoter of the
adenovirus E2 gene (171 , 172 , 363). E2F-mediated transcription was stimulated by the
adenovirus E 1 A protein and these events correlated with two forms of E2F , a "free" E2F
and a "complexed" E2F (10). Soon after, Rb was found to be a par of the "complexed"
E2F(11 , 14 52) and E1A was found to bind (348) and inhibit RB (11 , 14 49). These
results led to a model where the complexed E2F was constituted by RB binding and
repressing E2F function, and when RB was inactivated, the free E2F was derepressed and
able to activate transcription. Although these observations held tre for the activator class
of E2Fs, the model needed to be rethought once it was observed that E2F/Rb complexes
could actively repress transcription (117 , 346).
Currently, there are three types of E2F complexes: activator complexes, inhibited
complexes, and repressor complexes (Figue 1.5)(57, 84, 235). The activator complexes
are E2F/DP heterodimers that actively transactivate promoters. The inhibited complexes
are formed when Rb is bound to the activator complex. When Rb binds , it blocks the E2F
transactivation domain and makes the complex fuctionally inert. Finally, active
repressor complexes are generated when RB family members are recruited to DNA and
actively assemble a repressor activity.
The RB family members mediate repression of E2F fuction three ways. One way
they exert this function is by directly binding and blocking the transactivation domain of
E2F (95 , 124). Additionally, RB is known to bind many proteins involved in chromatin
remodeling, such as DNA methyltransferases and histone deacetylases, which actively
repress target gene transactivation (31 , 205, 208 , 215 , 296). It has also been observed that
RB can physically inhibit pre-initiation complexes from forming at promoters , thereby
inhibiting adjacent transcription factor function (279).
There are four known mechanisms by which RB can be inactivated. RB
inactivation occurs normally during regulated cell cycle progression, where the
phosphorylation status of RB and activation of cyclin/cdk complexes is coordinated with
the phase of the cell cycle, as described previously (25). The other three mechanisms for
RB inactivation result in cell cycle deregulation. One way Rb is inactivated is by genetic
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Figure 1.5: Schematics of the three types of E2F complexes.
(A) Active complex. Free E2F/DP heterodimers can actively transactivate gene
promoters. (B) Inibited complex. Rb binds to the transactivation domain of E2F
and inhibits the transactivation activity of the E2F/DP complex. (C) Repressed
complex. Active repressor complexes are formed when chromatin remodeling
enzmes are recruited and prevent target gene transcription.
inactivation, as observed in most cancers (234, 295, 301 , 302). Additionally, viral
oncoproteins from DNA tumor viruses target the RB proteins (127). Finally, Rb is
degraded by caspases following apoptotic stimuli (77).
C. Cell Cycle Deregulation
RB Targeting by ViralOncoproteins
Although the different RB family members are periodically activated and
inactivated throughout the cell cycle, all three proteins are inappropriately inactivated by
gene products encoded by DNA tumor viruses. Because adenoviruses, polyomaviruses
and human papillomaviruses (HPV) infect non-dividing, differentiated cells and do not
encode all the necessary machinery for replicating their viral genomes, they
inappropriately force the host cells into S-phase in order to hijack the host cell replication
machinery (127, 178). Although each virus has a unique mechanism for inactivating the
RB members, the overall effect of expression of adenovirus E1A, polyomavirus large T
antigen, or HPV E7 is the derepression of proteins and E2F target genes that are needed
for cell cycle progression and DNA synthesis , thereby allowing the virus to generate a
productive infection (127 , 178).
Unlike the other DNA tumor vIruses, adenovirus needs E2F for viral gene
expression as well as the expression of gene products needed for replication (233).
Adenovirus accomplishes this task by encoding E1A. There are two conserved regions
CR1 and CR2, on E1A that facilitate binding to all threeRB family members in the
pocket domain (127 , 178). Within CR2 there is an LxCxE motif that anchors E1A to RB
(86, 88 , 349). However, this interaction is not sufficient for blocking the Rb/E2F
interaction (91 , 138 , 144). The expression of the CR1 fragment alone directly antagonizes
Rb/E2F binding because the CR1 and E2F binding sites on Rb overlap (91 , 138, 144).
Currently, there is a two-step model proposed for the mechanism ofE1A mediated pocket
protein inactivation (91 , 144). In this model, E1A binds to Rb through the LxCxE motif
in CR2, which causes an increased local concentration of E1A that leads to the
dissociation of E2F. E1A also displaces other cellular factors that bind with the LxCxE
site, like HDAC1 , to relieve repression and can pertrb the phosphorylation and
acetylation status of Rb (127), although the role for altering these posttranslational
modifications is stil unclear.
Like E1A, the polyomavirus large T antigen contains CR1 and CR2 domains that
have sequence similarity to E1A (127, 178). It has been shown that simian virus 40
(SV40) large T binds all three RB proteins via an LxCxE motif in CR2 and this sequence
must be intact for E2F dependent transcription and bypassing pocket-protein mediated G
arrest (65 , 85 , 156 203 204). Using SV40 , large T was shown to bind Rb in a cell cycle
regulated manner by preferentially binding hypophosphorylated Rb in G , dissociating
from Rb when it is hyperphosphorylated, and reassociating with Rb in mitosis when it is
again hypophosphorylated (203 , 204). A unique featue of large T is the "1" domain
within CR1 , which shares functional similarity to the DnaJ chaperone protein of E. Coli
(164). It is thought that once large T binds RB/E2F complexes via the LxCxE motif in
CR2, the human HSC70 co-chaperone protein is recruited, which hydrolyzes ATP to
release large T, RB, and E2F from each other (127). In addition to causing the
dissociation of RB/E2F complexes, large T also alters the phosphorylation status of pI 07
and p130 , but not Rb (318), and induces the proteolysis ofp130, but not p107 or Rb (317
318). The mechanisms responsible for phosphorylation and proteolysis are stil unown.
The HPV E7 protein has CR1 and CR2 domains in the N-terminus, but it also
contains a large zinc finger in the C-terminal half of the protein (127, 178, 227 , 228).
Similar to E1A and large T, there is an LxCxE motif in CR2 that mediates binding to RB
and this motif is essential for E7 derepression of the cell cycle arrest (48, 86, 145).
However, unlike E1A, the CR1 ofE7 doesn t bind to Rb, but CR1 is needed for blocking
Rb/E2F interaction (48 , 138 355). It is thought that once Rb is bound to E7 at CR2 ' CR1
sterically hinders the E2F binding site on Rb (Figure 1.6) (127). Additionally, E7
expression insures E2F derepression by destabilizing the RB family members. Both the
CR1 and LxCxE motif are important for the proteasome-dependent degradation of RB
(22 , 112, 155).
hallmark of cancer ells is loss of proliferation control. Therefore, a
consequence of inactivating RB and perturbing its ability to control cell cycle progression
is the ability ofadenoviral E1A, SV40 large T, and HPV E7 to transform cells.
Adenovirus tye 12 was the first human virus shown to induce tumors in a rodent model
(330). Although it has not been isolated from human tumors, it can cooperate with the ras
oncogene to transform tissue culture cells (282). Similarly, SV 40 was isolated from
monkey kidney cells and demonstrated to be tumorigenic when injected into baby
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Figure 1.6: HPV E7 expression leads to RB inactivation and E2F deregulation.
E7 binding to RB disrupts the repression of E2F by RB, resulting in deregulated
E2F. Additionally, RB protein levels are diminished due to E7-induced RB
proteolysis in the proteasome. Adapted from (127).
hamsters (87, 110). Unlike adenovirus E1A, SV40 large T has been detected in some
human tumors (127) despite the fact that the virus ' normal reservoir is Rhesus Macaques.
Among the DNA tumor viruses, there are several "high-risk" strains of HPV that are
well-documented to have a cancer causative role in humans (369). These high-risk strains
are more efficient at inducing cell transformation and immortalization than low-risk
strains and the efficiency of transformation correlates with E7 activity as well (112 , 126
154). The E7 protein from high-risk strains binds to RB more efficiently and is more
effcient at degrading RB than the E7 proteins from low-risk strains (22 , 29, 103 , 230).
Consistent with this observation, E7 is always expressed in HPV positive tumors and
Rb/E2F complexes are not observed in tumors or cell lines that ectopically express E7
(227, 229). The importance of inactivating RB for transformation is highlighted by the
observation that the ability ofE1A, SV40 large T, or E7 to induce transformation requires
an intact LxCxE motif (127, 178 227 229).
Rb Inactivation in Cancer
In the early 1970' , a pediatrician, Alfred Knudson, recognized that children with
hereditary bilateral retinoblastoma were afflicted at an early age and that the rare, non-
hereditary unilateral retinoblastoma developed in individuals later in life. These
observations lead him to articulate his "two-hit" hypothesis, in which he speculated that
retinoblastoma results from two mutations , one of which would be inherited through the
germline , thereby decreasing the threshold for developing heritable tumors to one
mutation whereas non-heritable tumors would need two mutations (167). He and others
then went on to define tumor suppres ors as recessive genes that must undergo biallelic
inactivation for tumor development (60, 169 , 312). In the case of retinoblastoma, it was
shown that deletions or loss of a region on chromosome 13 was associated with both
heritable and non-heritable forms of the disease (42, 99, 168 , 237). Rb was later cloned
and identified as tumor suppressor located at that vital region of chromosome 13 (101).
We now know that Rb- regulated growth control is crucial to controlling cell
proliferation, which may explain why it is disrupted not only in retinoblastoma, but most
if not all , human tumors. Loss of Rb-mediated proliferation control dissociates the cell
cycle machinery from requiring extracellular signals for growth and dampens the ability
of cells to exit the cell cycle. The analysis of human tumors has ilustrated that there are a
wide spectrum of mutations that can affect the normal fuction of the Rb pathway (Figue
7), including mutations in amplification of cyclin/cdks that regulate Rb, silencing of
the INK4 locus, and as mentioned before, expression of small DNA tumor virus
oncoproteins (234, 295 , 301 , 302).
Mutations in the Rb locus are found in a subset of cancers, including
retinoblastomas, small cell lung carcinomas, and osteosarcomas (163, 195, 301 , 302).
Loss of Rb can be accomplished by a variety of mechanisms (295, 301 , 367). For
example, cells may have truncations or mutations that result in an unstable Rb transcript
and thereby have undetectable Rb protein levels. Deletion or loss of the Rb locus on
chromosome 13 is also commonly found in tumors. Additionally, mutations in the 
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Figure 1.7: Rb pathway inactivation in cancer.
(A) In normal cells, E2F levels are actively repressed by Rb , which is inactivated
by phosphorylation by , (;c1in D/cdk4 6. This complex is disrupted by p16INK4
binding. (B) When p16ln 
4 is silenced
, cyclin D/cdk4 6 activity is not regulated
resulting in increased E2F activity. (C) An Rb mutation results in deregulated E2F
activity. (D) Amplification of cyclin D or CDK4 results in hyperphosphorylated
, leading to deregulated E2F. (E) Expression of viral oncoproteins, like HPV
, leads to Rb inactivation and deregulation ofE2F.
promoter or at splice sites within the transcript have been documented. Lastly, in-frame
mutations resulting in stable Rb transcripts that have aberrant fuction also occur.
Proteins that regulate Rb function are also found mis-expressed in tumors (115
295 , 301). Many esophageal, breast and squamous cell carcinomas are associated with
amplification and translocation of cyclin DI. CDK4 has also been found to be amplified
in sarcomas and gliomas. Additionally, inactivation of the p16ink4 locus is a common
mutation in non-small cell lung carcinoma, breast carcinoma, pancreatic carcinoma, and
familial melanoma. Loss of p16ink4 results in overactive cyclin D/cdk4, elevated levels of
phosphorylated Rb, and E2F accumulation. Currently, it is believed that inactivation of
p16ink4 or amplification of cyclin DI/CDK4 is functionally equivalent to loss of Rb.
Consistent with this idea is the observation that tumors only deregulate one of the
proteins in this pathway. It is interesting to note that although the overall effect of these
mutations is to inactivate Rb and deregulate E2F , mutations in E2F have only recently
been found in some rare gastric and colorectal tumors (149, 319), suggesting that
mutation of E2F might be detrmental to emerging tumor cells.
Deregulated Proliferation and p53 Signaling
Considering that each human has trillions of susceptible cells
, the formation of a
tumor is a relatively rare event. Therefore, normal cells must be equipped to deal with
mutations that deregulate proliferation or other cell stresses, like DNA damage. One
major defense against the propagation of mutations is the p53 transcription factor.
Normally, this protein is maintained at very low levels within cells. However, following
cell stress, the p53 tumor suppressor is stabilized and activated (26, 119), serving to
protect the organism by preventing mutations from being passed to daughter cells.
The activation of p53 has two major effects: a cell cycle checkpoint and
programmed cell death. One of the gene products trans activated by p53 is the p21 CDKi.
The p21 protein is regulated primarily by transcription and its upregulation can elicit cell
cycle arrest in Gj/S (69 , 309) and Gz/M (33, 82 , 236 , 354). In response to cell stress
activation of a checkpoint allows the cell to tr and amend the situation. However, in
some contexts the stress or damage to the cell is too severe and additional p53 induced
genes can signal the elimination of the damaged cell. This programmed cell death, or
apoptosis, is an ordered signaling cascade resulting in chromosomal condensation, DNA
fragmentation, plasma membrane blebbing, and the formation of apoptotic bodies, which
lead to the demise of a cell (140). p53 transactivates many genes involved in the events
associated with apoptosis, including Apafl (96, 224). Apafl induction activates
Procaspase 9 , a protein belonging to a family of cysteine proteases called caspases, that
once active, generate many of the apoptosis related events (140). One event is the
activation of a caspase-activated DNase (CAD), also known as DNA fragmentation factor
(DFF), which fragments DNA by cleaving the DNA in nucleosomal increments (351).
First evidence that Rb inactivation generates a deleterious signal within a cell was
observed in cells expressing the adenoviral E1A oncoprotein, where E1A expression
induced apoptosis that was dependent on the regions ofE1A known to interact with Rb as
well as an intact p53 protein (64, 202). In fact, all of the small DNA tumor viruses encode
proteins to inactivate p53 to avoid the apoptotic response that their respective RB-
inactivating oncoproteins elicit. For the SV 40 polyomavirus, the inactivation of both RB
family members and p53 is accomplished by expression of the large T antigen (2, 127
178). A rodent model has been developed in which mice express a portion of the SV40
large T antigen (TgTl2) that inactivates RB but not p53 in the brain (50). High levels of
apoptosis as measured by TUNEL staining were observed in tissue expressing TgTl2;
however, when these mice were crossed to p53- mice, the TUNL staining was
significantly decreased, yet these mice rapidly develop aggressive brain tumors (320).
Similar observations have been made in mice containing Rb andp53 mutations (207 , 221
352). Because of the connection of Rb inactivation and p53-induced apoptosis, it is not
surprising that tumors are pressured to inactivate the p53 pathway.
Inactivation of Rb as well as ectopic expression of the activator E2Fs, leads to
unchecked proliferation in rodent models. The generation of mouse embryos that lack 
and E2FI (334) and the crossing of the TgTl2 mouse with an E2FI deficient mouse
(247) indicated that both the ectopic S phase entr and p53- induced apoptosis
phenotypes can be attributed to deregulated E2F1. Similarly, a transgenic mouse in which
E2F 1 is ectopically expressed in the skin showed high levels of BrdU incorporation and
apoptosis (261 , 262). Additionally, E2FI deficient mice have a defect in thymocyte
apoptosis, and consequently a subset of these mice develop thymomas (94) as well as
tumors of the reproductive tract and lung (362). These mouse models reveal an intricate
link between inappropriate proliferation signals caused by Rb inactivation and E2F 
deregulation, and p53-induced apoptosis as a means to protect against the development of
tumors.
Although p53 is not a direct transcriptional target of E2F1 , expression of E2F1
leads to p53 protein accumulation (131 , 173). One potential mechanism for this signaling
pathway is through activation of p19 jp14ARF and Mdm2. E2F1 trans activates the
murne pI~rf as well as the human p14ARF promoters (18 , 146, 273). The p19Arfjp14
gene product modulates the E3 ubiquitin ligase activity of Mdm2 by sequestering Mdm2
in the nucleolus (267 , 365). Because p53 is normally maintained at low levels in cells by
its ubiquitination by Mdm2 and subsequent degradation by the proteasome (100, 102
120, 134), activation of p19Arfjp14 RF and relocalizing Mdm2 could lead to p53
stabilization.
It is also well documented that p53 is covalently modified following a variety of
cell stresses. There are several phosphorylation sites in both the Nand C termini, and a
number of kinases have been shown to phosphorylate these sites (26, 119, 161).
Additionally, p53 has been shown to be acetylated, sumoylated, and most recently
neddylated (26, 119, 161). Currently, it is unclear which combination of post-
translational modifications is necessary for p53 activation in response to specific stresses.
However, it is clear that these modifications mediate p53 activity by increasing protein
stability and transactivation activity, as well as altering promoter specificity and protein
interactions. Most of the data on p53 covalent modification has been elucidated by
examining the response to different DNA damaging agents.
DNA Double Strand Breaks
DNA Repair Pathways
The DNA of a cell is continually faced with both intrinsic sources of damage, like
reactive oxygen species generated through normal metabolism, and extrinsic damaging
agents, like radiation. Because unrepaired or incorrectly repaired DNA may lead to cell
death, chromosomal aberrations, and in multicellular organisms, tumor formation, cells
are equipped to efficiently detect and repair lesions to their DNA. The cellular response
to different damaging agents is specialized and well conserved throughout evolution.
Mismatched or modified nuc1eotides affect a single strand of the DNA. Cells will
excise these lesions, resulting in a single strand break (SSB), and then repair the break
using the intact complementary strand of DNA (193). Defects in the repair systems for
SSBs are associated with high levels of point mutations and short regions of deletions and
insertions (186). However, cells that have damage that affects both strands of the DNA
like an inter-strand crosslink or double strand break (DSB), lack an intact
. complementary strand. Two major pathways exist to deal with this dilemma. First, non-
homologous end joining (NHEJ) is a homology independent system where two
independent DNA DSBs are rejoined end-to-end (193 , 240). The second pathway is a
homology dependent pathway, where the copying of several hundred base pairs from a
sister chromatid ensures faithful restoration of the DNA sequence (193 , 240, 359). Which
p.athway is initiated in response to a DSB in eukaryotic cells appears to be dependent on
the stage of the cell cycle (240). Defects in NHEJ and HR are associated with elevated
levels of chromosomal aberrations, including deletion or insertion of long chromosomal
material, and translocations (258). Because the free ends ofDSBs can physically separate
from each other, DSBs may be the most severe type of DNA damage for a multicellular
orgamsm.
DSB Response Signaling
The initial critical step in dealing with a DSB is sensing that a break exists.
Immediately following a DSB, a kinase based signaling cascade is initiated (Figue 1.8)
(193 , 240). Additionally, proteins are rapidly activated and recruited to the sites of the
breaks. These aggregated proteins form large clusters and are termed "foci", which can
be visualized by immunostaining for the individual counterparts. It is thought that the role
of the foci is to concentrate the proteins necessary for signaling repair and cell cycle
checkpoints, as well as prevent the dissociation of the two DNA ends that are liberated
following a break.
The current model focuses on a protein complex consisting of MRE 11 , RAD50
and NBS 1 (MRN) that rapidly localizes to the site of a DSB , as being the sensor of the
DSB. Each component of this complex has a precise role. MRE11 has both exonuclease
and endonuclease activity and is important in resecting the broken ends of the DSB prior
to repair (252 , 253 , 333). The hinge structure of the zinc hook in RAD50 enables it to
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Figure 1.8: Schematic of the DNA double strand break response.
Following a DSB , several response proteins are localized to the lesion, including
the MRN complex, yH2AX, and the ATM and CHK2 kinases. This signaling
cascade results in the phosphorylation, stabilization and activation of p53 , which
elicits a checkpoint or commences apoptosis.
hold the broken ends of the DNA in close proximity to allow for repair (63, 135). NBS1
is required for proper localization of the complex in response to a DSB (159, 353).
Following a DSB, a protein kinase signaling cascade is initiated by the
phosphatidylinositol 3-like kinases (PIKK), which include the ataxia telangiectasia
mutated (ATM) kinase and the ATM and Rad3- related (ATR) kinase. These kinases are
responsible for activating many proteins, including the checkpoint kinases, CHK1 and
CHK2 (161 , 193 , 240). Although ATM and ATR share some overlapping functions
A TM primarily phosphory1ates and activates CHK2 in response to irradiation and other
DSB agents (1, 212, 214). In an undamaged cell, ATM exists as a homodimer with a
strctue where the phosphorylation site for each subunit is masked by the other subunit.
Following a change in chromatin structure, like a DSB , the subunits phosphorylate each
other, causing dissociation into monomers (12), which are then free to phosphorylate
other target proteins to elicit the cell response to the break. MRN is believed to act
upstream of A TM based on observations that autophosphorylation of A TM and the
ATM-mediated phosphorylation of downstream target proteins are defective in cells
deficient for NBS1 (39, 136, 180, 181 , 336). Additionally, it was shown that MRE11
binds to broken DNA independent of ATM and the unwinding of DNA by MR was
required for ATM activation (180 211 218).
Interestingly, one of the substrates of activated A TM is the NBS 1 protein of the
MRN complex (104, 191 , 358 , 366). NBS1 also interacts with the phosphorylated form
of a histone protein (170), H2AX, which is phosphorylated by PIKKs, predominantly
ATM (34, 109, 254, 275 , 315). Within 1-3 minutes following induction of a DSB , the
carboxyl tail of H2AX is phosphorylated (termed yH2AX) (275) in the approximately 2
megabases of DNA surrounding the DSB (274). The role of yH2AX in DSB recognition
and repair is stil unclear. ' Although it is not needed for initial localization of the
components of MRN (43), yH2AX may help in the maintenance of these proteins at the
break site by binding to the NBS 1 component of MRN thereby assisting to tether the
broken DNA ends for repair.
One of the crucial A TM target proteins is CHK2 , which is known as an effector
kinase because of its important role in transmitting a checkpoint response following a
DSB (193 , 240). Expression of a dominant negative CHK2 (47) and examination of Chk2
deficient mice (322) showed the importance of Chk for p53 stabilization. N-termina1
sites of p53 , including serine 15 and 20, are phosphorylated by CHK2 in response to
irradiation and genotoxic agents (47 133 305). Additionally, A TM directly
phosphorylates p53 on serine 15 (45, 46, 83 , 176). As mentioned earlier, the
phosphorylation of p53 stabilizes the protein and enhances its transcriptional activity,
thereby allowing its target gene products to elicit a cell cycle checkpoint or apoptosis.
E2F and DNA Damage
It was shown that E2F 1 is necessary for efficient apoptosis induction in mouse
thymocytes in response to DNA damage (192). Additionally, E2F1 protein levels are
stabilized following DNA damage (139, 142, 192, 196 , 255, 314). There is a unique
ATM recognition site in the N-terminus that is phosphorylated in response to DNA
damage and this event is required for E2F1 protein stabilization (192). There is also a
CHK2 consensus site on E2F1 that is phosphorylated in response to DNA damage
resulting in increased half-life of E2F1 as well as heightened transcriptional activity and
localization to nuclear foci (314). These data indicate a specific role for E2F1 in response
to DNA damage that is unparalleled in the E2F family.
E. Genomic Instabilty
Genomic Instabilty and Cancer
The term genomic instability refers to genetic changes that result in disruption of
the normal organization and function of chromosomes. Structural genomic instability is
defined as changes in the genetic configuation of genes and includes translocations
insertions, and deletions. Numerical genomic instability is characterized by aneuploidy,
or an alteration in the number of chromosomes in a given cell. When both structural and
numerical changes are present in a single cell, the cell is said to be karyotyically
unstable. Because of the karyotyic changes frequently observed in tumor cells compared
to normal cells, it was hypothesized by Nowell that genomic instability facilitates the
The idea that tumor cell formation occurs as a step-wise accumulation of
progression of an emerging precancerous cell into a malignant cell (238).
mutations was first hypothesized in 1954 by Foulds (97). Evidence that this hypothesis is
tre comes from the observation that cancer does not arise from a single genetic
mutation. Instead, many genetic changes are required in order for a malignant cell to
develop. Currently, the notion of a "mutator phenotype" has evolved, where the
acquisition of specific mutations increases the mutation rate of that cell, thereby
enhancing the accumulation of genetic changes necessary for the emergence of a tumor
cell. (166, 197). Although the identity of the specific "mutator" is stil unkown, tumor
cells have several mutations in common including the Rb and p53 pathways.
Viral Oncoproteins and Genomic Instabilty
In addition to inducing quiescent cells into the cell cycle, inactivation of RB
family members by HPV E7 and adenoviral E1A expression induces genomic instability
(30 , 347). Much of the data has focused on E7-associated genomic instability, which has
been defined to include abnormal mitotic figues, such as centrosome and centriole
duplications (78 , 81), as well as anaphase bridges, which may result from DNA breaks
and/or lagging chromosome material (81). Furthermore, centrosome abnormalities have
and E1A disrupt normal centrosome duplication (30, 37 , 78- , 177), efforts to find a link
been detected in the cervix (13 , 272) and skin (290) of E7-expressing transgenic mice.
Additionally, expression of E1A has been shown to induce gaps and breaks in the
chromosomes of human embryonic kidney cells (37). Because it has become clear that E7
to Rb inactivation are underway. It is known that Rb helps control the reduplication of
centrosomes during S phase, and that overexpression of E2F1 or cyclin A can override
. this inhibition of reduplication by Rb (217). However, overexpression of CDK4 or
inactivation of p 16
INK4 is unable to overcome this inhibition by Rb (260), indicating that
the contribution of Rb inactivation to genomic changes is not yet fully understood.
Nuclear Oncogenes, microRNAs, and Genomic Instabilty
The observation that viral oncoprotein expression is associated with genomic
instability raises the possibility that some cellular oncogenes may also promote genetic
changes. Indeed, there is growing evidence that mis-expression of the c-MYC
transcription factor results in genomic instability via a variety of mechanisms. In normal
cells, c-MYC plays a major role in cell growth and cell cycle progression. However
when mis-expressed, c-MYC was shown to induce genomic instability through
chromosomal abnormalities, inappropriate replication ROS generation, and defective
DNA repair (24 , 160, 190 209 324 337).
A complex relationship exists between c-MYC and E2F1. For instance, c-MYC is
an E2F target gene (130, 137 326), suggesting that c-MYC may function downstream of
E2F. However, E2F is also a c-MYC target gene (93, 187), indicating that c-MYC may
function upstream of E2F. Additionally, both c-MYC (90, 128 , 342) and E2F1 (4, 173
174, 269, 299, 357) can signal apoptosis and whether c-MYC requires E2F1 to induce
apoptosis is controversial (19, 189). To complicate the relationship further, each protein
activates p53 via p19Arf/p14ARF -Mdm2 (18 , 68 , 89 , 368), but the pathways appear to be
independent of each other (19, 280). Whether deregulated E2F1 can induce genomic
instability, like c-MYC, either independently or dependently, has not yet been explored.
Mutations that result in mis-expression or deregulation of c-MYC are among the
most common mutational events in human cancers. Recently, it was shown that one of
the transcriptional targets ofc'-MYC is the mir-17-92 cluster ofmicroRNAs (miRNAs),
which is processed into six mature miRNAs: miR-17-5p, miR-18a, miR-19a, miR-20a
miR-19b- and miR-92- (122, 239). niiRNAs are a class of non-coding RNAs that are
produced by RNA polymerase II as capped, polyadenylated transcripts, termed primary
miRNAs (pri-miRNAs) (216). Pri-miRNAs are processed by the Drosha enzye
complex into smaller hairpin strctures, termed precursor miRNAs (pre-miRNAs), which
can then be exported from the nucleus into the cytoplasm by Exportin 5 (216). In the
cytoplasm, the pre-miRNAs are cleaved by the Dicer enzme into approximately 19-
nucleotide duplex RNA molecules (216). These mature miRNAs are unwound and
incorporated into RNA induced silencing complexes (RISC), which subsequently bind
and repress the translation of target message RNAs (216). miRNAs have been shown to
regulate the expression of gene products involved in development, differentiation
proliferation, and apoptosis (5).
Because the c-MYC protein is often upregulated in tumors, it may not be
surprising that the c-MYC trans activated mir-17- 92 cluster ofmiRNAs (122) was found
to be amplified in lymphomas ung cancers and several tumor cell lines (36, 121 , 122
341), suggesting another potential role for miRNAs in regulating the expression of gene
products associated with cancer. In fact, overexpression of the mir-17-92 locus, or a
fragment of the locus that encodes all of the mir-17-92 miRNAs except miR-92- in a
transgenic mouse that mis-expresses Myc under control of the immunoglobulin heavy-
chain enhancer (E!!-Myc) resulted in accelerated onset of B-cell lymphomas (122).
Additionally, the tumors showed enhanced staining for proliferation markers and
decreased staining for apoptosis (122). Although the individual contribution of miR-17-
5p, miR-18a, miR-19a, miR-20a and miR-19b- to oncogenesis, proliferation, and
apoptosis has not been fully elucidated, at least two of these c-MYC-regulated miRNAs
miR- 17- 5p and miR-20a inhibit the translation of E2FI (239). It has been suggested that
(239), but it has not yet been tested whether this increased E2F1 signals apoptosis.
overexpression of miR-17- 5p and miR-20a and the resultant decrease in E2F1 levels
may contribute to oncogenesis by reducing E2F1-induced apoptosis signaling (239).
Indeed, inhibition of miR-17-5p and miR-20a resulted in elevated E2F1 protein levels
Therefore, although it is not yet understood why c-MYC trans activates E2Fl message
and then limits its protein translation via miRNA expression, the complex regulation of
E2F1 underscores the importance of tightly controlling its activity.
F. Thesis goals
It has been known that Rb inactivation and the resultant deregulation ofE2F1 , but
not E2F2 or E2F3a, induces cellular apoptosis. The overall objective of this thesis was to
determine what makes E2F 1 toxic to cells. In Chapter III, we show that deregulated
E2F1- induced apoptosis signaling involves protein kinases that respond to DNA DSBs.
This signaling cascade becomes activated in normal human cells as a result of DSB
accumulation associated with the specific deregulation of E2F1. We also show that
acutely ablating Rb function by expression of the HPV E7 oncoprotein or transfection of
an siRNA designed to deplete Rb leads to DSB accumulation. Moreover, E2F1 does not
contribute to c-MYC associated DSBs, indicating that the DSBs associated with these
oncoproteins arise through independent mechanisms. In Chapter IV, we find E2F 1-
deregulation is toxic to cells and results in apoptosis, the data from this thesis also
associated DSBs in cancer cell lines that are 
Rb mutated in the absence of an exogenous
DSB stimulus. Th se basal, E2F I-associated DSBs are not observed in cancer cells lines
with Rb pathway mutations. We show that we can manipulate DSB levels in these cancer
cell lines by modulating Rb and E2F1 activity and suggest that these results may be
extended to a breast tumor organ cultue. Additionally, we find that small changes in
E2F1 activity result in DSB accumulation, by inhibiting c-MYC-transactivated miRNAs
klown to prevent E2FI translation. In addition to providing an explanation for why E2F1
suggest that E2F1-associated DSBs, and the complications arising when they are mis-
handled, are why E2F 1 levels are strctly monitored and regulated by the cell.
CHAPTER II:
MATERIALS AND METHODS
A. Cell Culture
Human Cell Lines
The following cell lines were maintained in Dulbecco s Modified Eagle Media
(DMEM) supplemented with 10% Fetal Bovine Serum (FBS) and 1 % Penicillin and
Streptomycin: NHF (human embryonic lung fibroblasts; ATCC GM01604), SaOS2 and
U20S (gifts from Steve Grossman, University of Massachusetts Medical School), MCF7
(gift from Sharon Cantor, University of Massachusetts Medical School), and DU145 (gift
from Lucia Languino, University of Massachusetts Medical School). NDF (normal
dermal fibroblasts; Coriell Cell Repository GM00316B), AT (ataxia telangiectasia
fibroblasts; Coriell Cell Repository GM05823C), and NBS (nijmegen breakage syndrome
fibroblasts; Coriell Cell Repository GM07166A) were maintained in DMEM
supplemented with 15% FBS and 1% Penicilin and Streptomycin. HeLa cells (ATCC
CCL-2) were maintained in Minimal Essential Media supplemented with 10% FBS and
1 % Penicilin and Streptomycin. H1299 (gift from Lucia Languino, University of
Massachusetts Medical School) and C33A (gift from Jason Chen, University of
Massachusetts Medical School) were maintained in RPMI 1640 supplemented with 10%
FBS and 1% Penicilin and Streptomycin. The Rb and p53 genotype status for each cell
type is listed in Table 2.
Mouse Embryo Fibroblasts
"'..
Early passage wildtye and genetically matched p53- MEFs were a generous gift
from Steve Jones (University of Massachusetts Medical School). MEFs derived from
pI~rfI- mouse embryos were a generous gift from Charles Sherr(St. Jude Children
Research Hospital, Memphis, Tenn. ). MEFs derived from pI~rf--/p53
/- 
mouse embryos
were a generous gift from Gerard Zambetti (University of Tennessee, Memphis). MEFs
were cultued in Dulbecco s modified Eagle s medium (DMEM) supplemented with 10%
fetal bovine serum and 1 % penicillin-streptomycin.
B. Drug Treatment
Hydrogen peroxide (H ), etoposide, caffeine, and the reactive oxygen species
inhibitor, N-acetylcysteine (NAC), were purchased from Sigma. The caspase inhibitor
zV AD-fmk, was purchased from Alexis Biochemical. NAC and caffeine were added to
the media at the following final concentrations immediately following infection or
transfection: 10 mM NAC , 0. , 0. , 1.0, or 2.0 mM caffeine. For experiments using H
as a positive control, 1 mM H was added to the media 15 min prior to haresting. For
experiments using etoposide as a positive control, etoposide was added to the media at 30
I-M 45 min prior to haresting.
C. Adenoviral Vectors
Generation of Viral Vectors
Recombinant adenoviruses encoding p53 , E2F1 , E2F2, E2F3a, c-MYC, and E7
have been described previously (68 , 174 293 294). The p53N/C virus was generated by
homologous recombination from the p53N/C constrct generously provided by Karen
Vousden (National Cancer Institute , Frederick, Md.) (8). AdCon refers to control virses
that encode an empty expression cassette, green fluorescent protein, or galactosidase
and had no effect on parameters tested relative to mock infection (data not shown).
Viruses were propagated in 293 cells and purified by centrifugation through
cesium-chloride gradients. Virus titers were determined by immunohistochemical
staining for the adenovirus hexon protein with an anti-adenovirus antibody (Biodesign
International) and visualized by using a 3 diaminobenzidine substrate kit from Vector
Laboratories (41).
Virus Infection
Cells were washed once with phosphate-buffered saline (PBS), and serum-free
media containing the virus was added to the cells. Infections were carried out at 37 C in
5% carbon dioxide (C0 ) for 1h. The virus inoculum was then removed and replaced
with the appropriate media. Infected cells were then cultured under the conditions
described above. The multiplicity of infection (MOl) is 750 for human fibroblast
experimerits unless otherwise noted in the figure legend.
D. Immunohistochemical Staining for p53
Early passage wildtype or genetically matched pI~rf/- MEFs were infected with
AdCon, AdE2F1 , or AdE2F1e132 at an MOl of 100. At 48 hpi cells were washed three
times with PBS and then fixed for 15 min in 3.7% formaldehyde, followed by 15 min in
cold methanol. The cells were then washed in PBS- 5% Tween 20 and then incubated
with anti-p53 monoclonal antibody PAb421 (Oncogene Research Products) in the
presence of 1% bovine serum albumin in PBS- 5% Tween 20 for 45 min at room
temperature at 1 :400. Cells were washed three times with PBS- 5% Tween 20, and the
bound antibody was detected with a Vectastain3 diaminobenzidine substrate kit as
described by the manufactuer (Vector Laboratory).
E. RNA Interference
siRNA Transfections
NHFs were transfected using Lipofectamine 2000 and all cancer cell lines were
transfected using Oligofectamine as described by the manufacturer (Invitrogen). All
siRNA transfections were at 60 nM in Optimem media (Gibco), unless otherwise stated
in the figure legends. Transfection media was removed from NHFs after 4h and replaced
with culture media. Transfection media remained on the cancer cell lines for 12h, unless
otherwise noted. Control siRNAs (siCon) recognize GFP, retrovirus LTR, or a nonsense
pr'
sequence, which had no effect on parameters tested relative to mock transfection. The
siNS (5' UUUUUUUCCCCAAGGGGG-
sequences of the siRNAs are listed:
siGFP (5' -CGUAACGGCCACAAGUUC-
siL TR (5' -GAUCCAGCAUAUAAGCAGC-
siRbA (5' UGGUUCACCUCGAACACCC-
siRbB (5' UUCCUCCACACACUCCAGU-
siE2F1a (5' GGCCCGAUCGAUGUUUCC-
siE2F1b (5' CUGACCAUCAGUACCUGGC-
siE2F1c (5' - GUCACGCUAUGAGACCUCA-
siE2F3a (5' -AGCGGUCAUCAGUACCUCU-
siE2F3b (5' -CUGUUAACCGAGGAUUCAG-
sip53A (5' -GACUCCAGUGGUAAUCUAC-
sip53B (5' -GACCCAGGUCCAGAUGAAG-
siMad2A (5' -GACAGAUCACAGCUACGGU-
siMad2B (5' -AUAGCAUGGUGGCCUACAA-
siMad2C (5' UACGGACUCACCUUGCUUG-
2 ' O-methyl RNA Transfections
Oligofectamine (Invitrogen) was mixed with 20nM of the indicated 2' - O-methyl
RNAs in Optimem media (Gibco) as recommended by the manufacturer. During the
Oligofectamine:RNA complex reaction of the transfection
, cells were trpsinized and 5 x
cells were aliquotted into 15-mL conical tubes. The Oligofactamine: RNA complex
was combined with the cells and then the mixtue was plated. The control 2' -O-methyl
RNA sequence is directed against the luciferase gene (141). The sequences of the 0- 
methyl RNAs are listed (239):
miR-17-5p antisense (5' ACUACCUGCACUGUAAGCACUUUG-
miR-20a antisense (5' CUACCUGCACUAUAAGCACUUUA-
Luc antisense (5' - CAUCACGUACGCGGAAUACUUCGAAUGUCC-
F. Immunofluorescence
Coverslip Treatment
Glass coverslips were pre-treated with 40% HCI for 2 min followed by a 5 min
70% ethanol wash. Coverslips were then washed extensively in distiled water and
allowed to dry. Prior to plating cells, coverslips were treated with UV.
yH2AX Immunofluorescence
Cells were transfected with siRNAs as needed and after 24h were plated onto
treated coverslips at 4000 cells per cm
. Cells were infected 12h after plating and fixed
for immunostaining 24h later by washing with PBS and treating with 3.
II 
formaldehyde/PBS for 10 min at room temperatue (RT). Cells were washed with PBS
and then - C methanol was added for 30 min. Cells were washed with PBS
, blocked in
3% BSNPBS for 1h at RT, and incubated with yH2AX monoclonal antibody (Upstate
Biotechnology) for 1.5h at RT (see Table 2. 1 for antibody conditions for individual cell
types). Bound antibody was detected using Rhodamine Red- conjugated secondary
antibody (Jackson Immunoresearch Laboratories
, Inc.). Coverslips were mounted onto
slides using Hard Set Vectashield with 4'
, 6' Diamidino- phenylindole (DAPI) (Vector
Laboratories, Inc.
MRE 11 Immunofluorescence
Cells were transfected with siRNAs as needed and after 24h were plated onto
treated coverslips at 4000 cells per cm
. Cells were infected 12h after plating and fixed
for immunostaining 24h later by washing with PBS and treating with 
paraformaldehyde/200 mM sucrose/PBS for 30 min. Fixed cells were washed 3 times
with PBS , then permeabilized using 20mM HEPES pH 7.4/ 50mM NaCV 3 mM MgCh,l
300 mM sucrose/ 0.5% Triton-X 100 (218). Cells were blocked with 10% FBS/PBS for
1h at RT and incubated with MREll antibody (Genetex) at 1: 1000 for 1h at RT. Bound
antibody was detected using Texas Red conjugated secondary antibody (Southern
Biotechnology Associates, Inc.) at 1:250.
BrdU Immunofluorescence
Serum-starved NHFs were transfected in suspension with 2' 0-methyl RNAs and
plated at 4000 cells/cm
2 onto coverslips. The transfection reaction was replaced with
media containing 10 !lM BrdU after 6h. Cells were then fixed 15, 18 , 21 and 24h later.
To fix, cells were washed twice with PBS , fixed in 90% ethanol in PBS for 10 min, and
then washed 2 times in PBS. Following fixation, cells were again washed twice with
PBS. The DNA was denatued in 2N HC1 for 30 min at RT. To neutralize theacid, O.
sodium borate was added to each well and aspirated. Cells were then extensively washed
in PBS , followed by a wash with PBS- T. Cells were then blocked in 1 % BSAlPBS- T for
10 min at RT and then incubated for 45 min at RT with monoclonal anti- BrdU antibody
(Accurate Chemical and Scientific Corporation) at 1: 1 00 in 5%FBS/PBSIO. % Triton-
Bound antibody was detected with rhodamine conjugated donkey anti-rat antibody
(Jackson Immunoresearch Laboratories) at 1 :200 in 5%FBS/PBS/0. % Triton-
Quantitation of Positive Cells
To quantitate the percentage of cells that were positive for yH2AX foci , MR11
foci , or BrdU incorporation, at least 200 cells per treatment were counted and considered
positive if they had 3 or more foci per cell. To determine the average number of foci per
cell, at least 50 nuclei of randomly chosen yH2AX positive cells were focused with a
100X oil immersion objective, the number of foci was counted, and the average number
;\;;:.
of foci per nucleus was calculated. Error bars represent the standard deviation of
experiments done in triplicate.
G. Neutral Comet Assay
Cells were transfected as needed and plated at 1xlO
s cells/ well of a 6 well plate.
Cells were infected with recombinant adenovirus 12h after plating. Experiments using
siRb were harvested 48h post transfection and all other experiments were harested at 24
hpi. As positive controls, cells were either treated with 30 M etoposide for 45 min or 
mM H 02 for 20 min prior to harvesting. Cells were processed for comet tail formation
using neutral comet. assay conditions according to the manufacturer
s instructions
(Trevigen). To harvest, cells were scraped in media, washed with cold PBS, and then
resuspended in PBS. Low melting point agarose at 42 C was gently added to the cells
and then the mixture was spread onto a comet slide and allowed to cool at 4 C in the
dark. Cells were then incubated in lysis solution for 30 min at 4 , washed in TBE
buffer, and then subjected to electrophoresis. Following electrophoresis, excess TBE was
removed and slides were immersed in ethanol for 5 min, then dred at RT overnght in the
dark.
Comets were analyzed using the measurement tool in OpenLab software. The
lengths of the comet head and tail were recorded for at least 50 comets on 2 separate
slides (total cell number? 1 00) per treatment. The ratio of tail length to head length was
calculated and cells with a ratio greater than or equal to 2 were counted positive for
DSBs. Figues show the percentage of cells positive for DSBs per treatment and the
standard deviation for experiments done in triplicate.
H. Apoptosis Analysis
Flow Cytometry Analysis
At 72 hpi, MEFs were trpsinized, combined with floating cells, and pelletted by
centrifugation at 500 x g for 5 min at 4 C. Pellets were washed with PBS , pelletted again
and then resuspended in 400 f!l of PBS. Cells were then fixed in cold ethanol (70 % final
concentration) and processed for propidium iodide (PI) staining as described previously
(174). Flow cytometric analysis was performed by the University of Massachusetts
Medical School Flow Cytometr Core Facility. Apoptotic cells were defined as the
population that contained less than a 2N DNA content.
ELISA Analysis of siRNA Transfected Cells
Cells were transfected as described above. After 24h, transfected cells were plated
into 12 well plates at 2 x 10 cells per well and viral infections were performed 12h after
re-plating. Cells were harvested at 72 hpi and analyzed using the Cell Death Detection
ELISAplus (Roche) protocol according to manufacturers ' instructions. The ordinate axis
represents the extent of apoptosis relative to control
, which is defined as 1. Error bars
represent the standard deviations calculated from an experiment performed in triplicate.
ELISA Analysis of Virus Infected Cells
Cells were plated in 24'-well plates at a concentration of 1 x cells per well.
Virus infections were performed 12h after plating. Apoptosis in murine cells was
analyzed at 72 hpi and in human cells at 96 hpi using the Cell Death Detection ELISA
plus
(Roche) protocol according to manufacturers ' instructions. The ordinate axis represents
the extent of apoptosis relative to control, which is defined as 1. Error bars represent the
standard deviations calculated from an experiment performed in triplicate.
I. Immunoblot Analysis
Whole cell extracts were harvested from cells infected with recombinant
adenovirus or cells transfected with 2' 0-methy1 RNAs at 24h. Cells transfected with
siRNAs were harested at 48h post transfection. Cells were washed twice with cold PBS
and lysed in 50 mM HEPES/ 2 mM magnesium ch10ride/ 250 mM sodium chloride/ 0.
mM ED TN 1 mM EGTN 1% Nonidet P-40/ 1 mM dithiothreitol/ Ix mammalian
protease inhibitor cocktail (Sigma)/ Ix phosphatase inhibitor cocktails I and II (Sigma) by
incubating on ice for 30 min, followed by sonication. Soluble proteins were separated by
centrifugation at 13 000 x g in a microcentrifuge and supernatants 
were stored at -
Proteins were separated by SDS-P AGE analysis and transferred to PVDF membrane
(Perkin Elmer) by e1ectroblotting. E2F1 and E2F3a were detected using the polyclonal
antisera C-20 and C- , respectively (Santa Cruz Biotechnology) at 1 :500. p53 and Rb
were detected using monoclonal antibodies at 1:500 and AFll at 1:600
, respectively (Calbiochem). Transduced p53N/C and wild-tye p53 were detected with the
monoclonal antibody PAb1801 at 1:500 (Oncogene Research Products). MA2 levels
were detected using the monoclonal clone 48 antibody (BD Biosciences). Actin levels
detected using polyclonal antisera 1- 19 at 1:2000 (Santa Cruz Biotechnology) are shown
protein loading controls. Immunoreactive proteins were detected
chemiluminescence (Perkin Elmer).
J. Human Breast Tissue Organ Culture
Organ Culture Acquisition and Maintenance
Normal breast tissue was derived from reduction mammoplasties and tumor breast
tissue was obtained from mastectomies performed at UMass affiliated hospitals.
Following procurement by Andrew Fischer (Director of Cytopathology, UMass Medical
School), tissues were sliced into approximately 3mm3 sections, placed into 6 well plates
, .
and allowep to equilibrate in DMEM without seru for 2.5h.
Organ Culture Infection with Recombinant Adenovirus
Equilibration media was removed from tissue slices and DMEM containing virus
was placed in the well. Plates were gently rocked every 5 min during the infection
incubation. After 2h, DMEM containing 5% FBS and 1 % Penicilin and Streptomycin
was added to each well.
Organ Culture Tissue Sectioning and Staining
At the iridicated time post infection, organ cultues were fixed in cytorich red
cytology preservative. Tissues were then embedded in paraffn wax and sectioned using a
microtome. Tissue sections were baked, the paraffn wax was removed, and the sections
were rehydrated. Hematoxylin and eosin staining for analyzing tissue morphology,
immunohistochemistry for analyzing infection levels, or co-immunofluorescence for
detecting levels of DSBs and infection was then performed.
For the co-immunofluorescence, antigen retrieval was performed by boiling slides
in O.OlM sodium citrate/ 1 mM EDT A pH 6.0. Slides were then blocked in 3% BSAlPBS
for 1h at RT and incubated in an anti-GFP monoclonal antibody (Santa Cruz) at 1 :200 
5% FBS/0. 1% TritonXPBS for 45 min at RT. Bound antibody was detected using a
Texas red conjugated antibody ' (Southern Biotech) in 5% FBS/0. 1 % TritonXPBS at
1 :500. Slides were washed extensively in PBSIO. 1 % TritonX and then blocked again in
3% BSAlPBS. For yH2AX protein, tissues were incubated in a biotin-conjugated anti-
yH2AX (Upstate) at 1:200 in 5% FBS/0. 1% TritonXPBS for 45 min at RT. Bound
pnmary antibody was detected with streptavidin-conjugated pacific blue secondary
antibody (Molecular Probes) at 1 :400 in PBS- T.
Summary of Human Cell Lines
yH2AX Antibody Dilutions
Cell Line Cell Type p53 Priary Secondary
NHF Nonnallung fibroblast I : 1250 1 :2000
NDF Nonnal human dermal fibroblast 1: 1250 1:1500
Ataxia telagiectasia derml fibroblast 1: 1250 1 : 1500
NBS Nijmegen breakage syndrome dennalfibroblast 1 : 1250 1:1500
SaOS2 Osteosarcoma mut mut 1:500 1:1000
mas Osteosarcoma 1:500 1 : 1000
MCF7 Breast carcinoma 1 :1250 1:1500
DU145 Prostate carcinoma mut mut 1: 1000 1:1500
H1299 Non-small cell lung carcinoma mut 1 : 1250 1:1250
C33A Cervical carcinoma, HPV negative mut mut 1: 1000 1:1000
HeLa Cervical carcinoma, HPV positive 1: 000 1 : 1500
Table 2.1: Summary of human cell lines.
The Rb and p53 genotye status of the human cell lines are listed as well as the antibody
dilutions for y H2AX immunofluorescence.
a: Truncation mutation: SaOS2 (304), DU145 (27), C33A (291)
b: Homozygous deletion: SaOS2 and H1299 (257)
c: Point mutation: DU145 (P274L and V223F (38)), C33A (R273C, (291))
CHAPTER III:
RB INACTIVATION LEADS TO E2Fl-
MEDIATED DNA DOUBLE STRAND
BREAK ACCUMULATION
A. Introduction
Mutations resulting in inactivation of growth control pathways are essential for
the formation of cancer, which likely explains why most cancer cells have mutations that
inactivate the retinoblastoma tumor suppressor (Rb) (115 , 234, 295 , 301). Inactivation of
Rb results in the derepression of the activator class ofE2F proteins , namely E2F1 , E2F2
and E2F3a. These E2F transcription factors transactivate many of the genes required for
DNA replication and S phase. In fact, all three activator E2Fs can potently stimulate
quiescent rodent cells to enter S phase when ectopically expressed (68, 153, 174).
Genetic studies in mice have demonstrated that uncoupling Rb regulation of E2F by
inactivating Rb leads to apoptosis that is dependent on the p53 transcription factor (247
334). It was later shown that the ability to induce p53 dependent apoptosis is unique to
E2F1 among the E2F family members (4 173, 174 269 299 357). These observations
highlight a conundrum: expression of all three activator E2Fs potently induces S phase
progression in rodent models; however, only expression of E2F 1 efficiently induces p53
dependent apoptosis. Therefore, deregulated E2F1 must generate an additional signal to
stimulate cells to undergo apoptosis.
Because Rb inactivation causes quiescent cells to enter the cell cycle, small DNA
tumor viruses like Human Papilomavirus (HPV) encode oncoproteins that inactivate the
RB family of proteins, thereby facilitating the replication of its viral genome by
exploiting the host cell' s replication machinery. In addition to inactivating the RB
proteins , HPV E7 induces genomic instability in diploid human fibroblasts (347). More
recently, this genomic instability has been defined to include abnormal mitotic figures
such as centrosome and centriole duplications (78, 81), as well as anaphase bridges
which may result from DNA breaks and/or lagging chromosome material (81). However
the extent to which Rb inactivation contributes to genomic changes is not yet fully
understood. Given the link between E7 expression and genomic instability and the
observation that E7 expression can result in apoptosis that is dependent on E2F1 (278),
we hypothesized that deregulated E2F 1 resulting from Rb inactivation may lead to
changes in genomic stability, which could be the E2F1-specific signal that induces p53-
dependent apoptosis.
B. Results
pl~rf contributes to E2Fl-induced p53 protein accumulation but is not required for
E2F I- induced p53 dependent apoptosis.
The mouse p19Arf (human p14ARF) promoter has E2F binding sites that are
responsive to ectopic lly expressed E2F1 (18, 146, 273). Given that p19Arf expression
leads to increased p53 levels via inactivation of Mdm2 (267 , 365), we asked whether
E2F1-induced p53 protein accumulation requires pl~rf To address this question
wildtye and l~rf- mouse embryo fibroblasts (MEFs) were infected with recombinant
adenovirus encoding E2F1 (AdE2F1) or a control (AdCon) and levels of endogenous p53
were examined by immunohistochemistry. We found that E2F1 expression efficiently
induced p53 protein levels in wildtye MEFs (Figure 3. 1). Compared to AdCon infected
cells, increased p53 levels were also observed in E2F1 infectedpl~ifI- MEFs, albeit to a
lesser extent than in the wildtye MEFs. Expression of an E2F1 DNA binding mutant
E2F1 e13, did not result in an increase in p53 in either genetic background. These results
suggest that p 19
Arf plays a role in mediating p53 levels in cells ectopically expressing
E2F 1.
Because of the link between E2F 1 and p53-dependent apoptosis, we then asked
whether p19Arf was required for E2F1-induced p53 dependent apoptosis. When E2F1 was
expressed in wildtye and plgAifl- MEFs, we found that levels of apoptosis as measured
by the percentage of cells with less than 2N DNA content were similar regardless of
wildtype
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Figure 3.1: E2Fl induces p53 protein accumulation independent of 
Wildtype and pl~rf- MEFs were infected with recombinant adenoviruses
encoding E2F1 , a DNA binding mutant ofE2F1 (E2F1 e13), or a control. At 48 hpi
cells were fixed and immunohistochemistry was performed for p53 levels.
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Figure 3.2: E2Fl induces p53-dependent apoptosis in the absence ofpl
Wildtypeandpl~rf-- MEFs (A) or pl~rf- andplgArf--/p53-1- MEFs (B) were
infected with AdCon or AdE2F1 at an MOl of 500. At 24 hpi , cells were
harvested, stained with propidium iodide and analyzed for DNA content by
F ACS analysis. Graph represents percentage of cells with o:2N DNA content.
pl~rf status (Figure 3.2A). Additionally, the E2F1-induced apoptosis observed in the
plgA f- MEFs was dependent on p53 , because the ability ofE2F1 to induce apoptosis in
plgArfI-/p53-1- MEFs was compromised (Figure 3.2B).
Phosphorylation ofp53 by DNA damage response kinases contributes to E2Fl induced
apoptosis.
Because covalent modification of p53 is a known mechanism of stabilizing and
activating p53 , we asked whether phosphorylation of p53 plays a role in E2F1-induced
apoptosis. To address this question, we constructed a recombinant adenovirus encoding a
p53 mutant in which many of the Nand C terminal residues known to be phosphorylated
in response to DNA damage were changed to alanine (8). This mutant, p53N/C, is
regulated by Mdm2; hence the half-life of this mutant is similar to the half-life of
wildtye p53 (8). We found that expression levels of p53N/C are similar to the levels of
wildtye p53 when expressed in p53-1- MEFs (Figure 3.3A). To determine whether the
phosphorylation of p53 contributes to E2F1-induced apoptosis p53- MEFs were
transduced with AdE2F1 , AdE2F2, or AdCon and either wildtye Adp53 or mutant
Adp53N/C. In cells expressing wildtye p53 , E2F1 expression induced apoptosis.
However, this E2F1-induced apoptosis was compromised in cells expressing the p53N/C
mutant (Figure 3.3B). Ectopic expression ofE2F2 ora control did not induce apoptosis 
fibroblasts, regardless of the p53 status of the cells. These results suggest that
phosphorylation ofp53 contributes to E2F1- induced apoptosis.
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Figure 3.3: Phosphorylation of p53 correlates with apoptosis.
(A) Western blot analysis. p53- MEFs were infected with Adp53 or Adp53N/C at
the indicated MOls. At 24 hpi, lysates were generated and analyzed for p53
expression levels. Actin levels are shown as a protein loading control. (B)
Apoptosis assay. p53- MEFs were infected with AdCon, AdE2F1 , or AdE2F2 at
an MOl of 500 and were co-infected with Adp53 or Adp53N/C at an MOl of 20.
Cells were harvested, propidium iodide stained, and subjected to F ACS analysis at
72 hpi. Numbers in upper-right quadrant indicate the percentage of apoptotic cells
with ,2N DNA content.
The phosphorylation of p53 is a common event following a variety of DNA
damage stimuli. Treating cells with caffeine prior to y-irradiation, prevents the
accumulation of p53 protein by inhibiting the activation of the DNA damage response
kinases, ATM and ATR (162), which phosphorylate p53 on serine 18 (161). To
determine whether inhibition of A TM and A TR would attenuate the ability of E2F 1 to
induce p53- dependent apoptosis, increasing doses of caffeine were added to wildtye
MEFs transduced with AdE2F1. We found that E2F1-induced apoptosis was decreased
by treatment with caffeine in a dose-dependent manner (Figue 3.4). These results
implicate the DNA damage response kinases, A TM and A TR, as participating in the
signaling cascade by which E2F1 induces apoptosis.
We next examined whether cells lacking functional A TM protein would be
resistant to E2F1- induced apoptosis. Dermal fibroblasts from a patient with ataxia
telangiectasia (AT) were infected with AdE2F1 or AdCon, and apoptosis levels were
measured. We found that ectopic expression of E2F 1 efficiently induced apoptosis in
dermal fibroblasts from a normal patient. However
, the ability to induce apoptosis in the
AT fibroblasts was attenuated (Figure 3.5). These results indicate that functional ATM
plays a role in E2F1-induced apoptosis and suggests that deregulated E2F1 activates
DNA DSB signaling molecules.
E2F expression results in the formation of DNA damage recognition foci and DSB
accumulation.
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Figure 3.4: E2Fl inducedapoptosis signaling is caffeine sensitive.
Wildtype MEFs were infected with AdCon or AdE2F1 at an MOl of 500
and immediately following infection, caffeine was added to the media at the
indicated doses. At 72 hpi, cells were analyzed for apoptosis.
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Figure 3.5: E2Fl induced apoptosis is compromised in AT cells.
NDF and AT cells were infected with AdCon or AdE2F1 at an MOl of
1000. Cells were harvested at 96 hpi and analyzed for apoptosis.
Because DNA damage response kinase activation and p53 phosphorylation are
events that occur in response to DSBs
, we asked whether the cell' s response to ectopic
E2F1 expression mimics the cellular response to DSBs. To address this question
, normal
human fibroblasts (NHFs) infected with recombinant 
adenoviruses that encode E2F1 or
another activator E2F protein
, E2F3a (AdE2F1 and AdE2F3a
, respectively) were
immunostained for localization of the phosphorylated form of the H2AX histone protein
(yH2AX) to discrete foci (Figue 3.6A). In response to DSBs
, H2AX is phosphorylated
and localizes adjacent to the sites of the breaks (17
, 44, 219, 254, 275). Approximately
78.4% of cells overexpressing E2F1 induced yH2AX foci formation (Figue 3.6B),
whereas background levels were approximately 5.3%. However
, cells transduced with
AdE2F3a were unable to induce yH2AX foci formation even when the multiplicity of
infection (MOl) of AdE2F3a was increased 2-fold or 3-fold. As a positive control
virtally all of the cells that were treated with the topoisomerase II inhibitor
, etoposide
localized yH2AX into foci. These results suggest that E2F 1 expression specifically
generates a signal similar to that produced in response to DSBs.
To determine whether E2F1 expression results in an accumulation of DNA DSBs
we performed neutral comet assays
, which specifically detect DSBs (243
, 244, 289, 327)
(Figure 3.7A). Cells were scored positive for DSBs when the length of the comet tail was
at least 2 times the length of the comet head. Using this stringent criterion
, we found an
approximate4-5 fold increase in the percentage of E2F1 expressing 
cells with DSBs as
compared to control cells (34.6% and 7.2% respectively) (Figure 3.7B). Increasing MOIs
of AdE2F3a (Figue 3.7) or another activator E2F family member
, AdE2F2 (data not
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Figure 3.6: Ectopic E2Fl expression specifcally leads to y H2AX foci formation.
NHFs were infected with AdCon, AdE2F1 , or increasing doses of AdE2F3a. At 24
hpi, cells were fixed and immUlostained for yH2AX positive cells (A). (B)
Quantitation ofyH2AX positive cells.
....
Treatment Dose % Positive
1 mM 92.5 :t 1.
AdCon 3000 2:t1.
AdE2F1 1000 34.6 :t 3.
AdE2F3a 1000 2 :t 1.
2000 8 :t 1.
3000 6 :t 1.
Figure 3.7: Ectopic expression of E2Fl specifcally leads to DSBs.(A) NHFs were infected with AdCon
, AdE2F1 , or increasing doses of AdE2F3a
at the MOIs listed in (B) and harvested for neutral comet assay at 24 hpi. Cells
were treated with hydrogen peroxide (Hz ) as a positive control. Yellow
arrowheads indicate cells positive for DSBs. (B) Quantitation of neutral comet
assay. Cells were treated as in (A) and analyzed for comet tail formation at 24
hpi.
shown), did not cause comet tail formation
, indicating that DSB accumulation appears to
be a unique propert of deregulated E2F 1.
Expression of HPV E7 results in the formation 
of DNA damage recognition foci and DSB
accumulation.
Expression of HPV E7 inactivates the RB family of proteins and 
subsequently
deregulates E2F (48
, 138, 246, 251). We asked whether deregulation of endogenous
E2F1 by expression of E7 leads to an accumulation of DNA damage. To address this
question, normal human fibroblasts (NHFs) were infected with AdE7 and immunostained
for localization of yH2AX foci (Figure 3. 8A). We found that approximately 65% of E7
expressing NHFs localized yH2AX into foci compared to less than 5% in control infected
cells (Figure 3.8B).
Consistent with our detection of yH2AX foci as a response to potential DNA
breaks, E7 expression in keratinocytes leads to DNA breaks as assessed by alkaline
, comet assay (81). By performing neutral comet assays to 
specifically detect DSBs
, we
found that similar to ectopic expression of E2F1
, there was an approximate 4-5 fold
increase in the percentage of E7 expressing cells with DSBs as compared to control cells
(32. 1 % and 7.8% respectively) (Figure 3.9B). These results indicate that DSBs
accumulate in cells that express HPV E7.
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Figure 3.8: HPV E7 expression leads to y H2AX foci formation.
(A) yH2AX foci localization. NHFs were infected with AdCon or AdE7 and
analyzed for yH2AX localization 24 hpi. Cells were treated with etoposide as a
positive control. Foci are visualized with rhodamine (red); the nuclei are DAPI
stained (blue). (B) Quantiation ofyH2AX positive cells. Cells were treated as
in (A) and scored for foci formation 24 hpi.
Jil 8
Treatment % Positive
81.8 :t 8.
AdCon 8:t 0.
AdE7 32. 1 :t 1.
Figure 3.9: HPV E7 expression leads to DSB accumulation.
(A) Comet tail formation. NHFs were treated with etoposide or infected with
AdCon or AdE7. At 24 hpi, cells were analyzed for DSBs by neutral comet
assay. DNA from individual cells is visualized with SYBR Green. Yellow
arrowheads indicate cells positive for DSBs. (B) Quantitation of neutral comet
assay. Cells were treated as in (A) and analyzed for comet tail formation at 24
hpi.
Inactivating Rb results in p53 accumulation, apoptosis, yH2AX foci formation and DSB
accumulation.
To determine whether the inactivation of Rb by E7 is responsible for the observed
DSB accumulation, we designed siRNAs to deplete Rb (siRb). Two of the tested Rb-
specific siRNAs decreased Rb levels (Figue 3. 10A) and subsequently lead to p53
accumulation (Figue 3. lOB) and apoptosis (Figures 3. lOC and 3. lOD). When yH2AX
foci localization was examined, we found that siRbA transfected NHFs localized yH2AX
into foci (Figue 3. 11A) in approximately 35% of the cells, compared to about 7% of
control siRNA transfected cells (Figue 3. 11B). In addition, there was a 5-fold increase in
the percentage of siRb transfected cells positive for DSB accumulation compared to
siCon transfected cells as measured by neutral comet assay (Figure 3. 12). These results
suggest that the accumulation of DSBs that occurs when E7 is expressed is likely due to
the inactivation of Rb by E7.
DSB accumulation and yH2AXfociformation requires E2Fl.
Additional data from our laboratory have shown that A TM and CHK2 are
activated by E7, and the activation of these proteins is dependent on E2F1 (278). We
hypothesized that the DSB accumulation observed in E7 expressing cells may be due to
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Figure 3.10: Rb Depletion results in p53 accumulation and apoptosis.
(A and B) Western blot analysis. NHFs were transfected with siCon, siRbA or
siRbB. Lysates were harvested 48h post transfection and analyzed for Rb levels (A)
or p53 levels (B). (C) Light microscopy. Bright field images of NHFs transfected
with siCon or siRbA 72h post transfection. (D) Apoptosis assay. Cells were
transfected with siCon, siRbA, or siRbB and were analyzed for apoptosis 72h post
transfection.
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Figure 3. 11: Rb depletion leads to yH2AX foci formation.
(A) yH2AX foci localization. NHFs were transfected with siCon or siRbA and were
analyzed for yH2AX localization 48h post transfection. Cells were treated with
either etoposide or H20 as positive controls. Foci are visualized with rhodamine(red); the nuclei are DAPI stained (blue). (B) Quantiation of yH2AX positive cells.
Cells were treated with etoposide or transfected with siCon
, siRbA, or siRbB and
scored for foci formation 48h post transfection.
Etoposide H siCon siRbA
!....
% PositiveTreatment
Etoposide 87.6:1 2.
88.6 :I 0.
siCon 5:1 0.
siRbA 32.2:1 0.
siRbB 35.7:1 0.
Figure 3.12: Rb depletion leads to comet tail formation.
(A) Comet tail formation. NHFs were transfected with siCon or siRbA were
analyzed for comet tails 48h post transfection. Cells were treated with either
etoposide or H as positive controls. DNA from individual cells is visualized
with SYBR Green. Yellow arrowheads indicate cells with DSBs. (B) Quantiation
of neutral comet assay. Cells were treated as in (A) and analyzed for comet tail
formation 48h post transfection.
deregulated E2F1 caused by Rb inactivation. To test this hypothesis
, we transfected
siRNAs designed to deplete E2F1 (siE2F1) into NHFs. Two of the three 
siRNAs that
were tested effectively depleted E2F1 levels (Figue 3. 13A). The transfected cells were
subsequently infected with AdE7 and immunostained to determine whether yH2AX
localized to foci. E7 expressing cells transfected with 
siE2F1 had a substantial decrease
(80.7% vs. 26.4%) in the percentage of cells positive for yH2AX foci formation
compared to transfection with a control siRNA (Figure 3. 
13B). To determine whether the,
ability to induce foci formation was restricted to E2F 1
, we transfected siRNAs designed
to deplete E2F3a, which is also negatively regulated by Rb. Importantly, E7 expressing
cells that were transfected with siRNAs directed against E2F3a showed 
virtally no effect
on yH2AX foci formation, despite the effcient reduction ofE2F3a levels (Figure 3. 13).
Additionally, we looked at the ability of another DNA damage response protein
MREll , to localize into DNA damage foci
, an event that is independent ofyH2AX (43
219). Similar to yH2AX localization
, we found that E7 expression leads to MRE11 foci
formation (Figure 3. 14A) Furhermore, the E7-associated MRll foci formation is
disrupted when cells are transfected with siE2F1 but remain intact when cells are
transfected with siE2F3a (12.6% compared to 56.5%) (Figue 3. 14C), despite efficient
depletion of the targeted protein (Figure 3. 14B). These results suggest that deregulated
E2F1 is responsible for the observed DSB accumulation occurring when Rb 
inactivated.
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Figure 3.13: E2Fl is responsible for HPV E7 induced y H2AX foci
formation. (A) Western blot analysis of E2F1 and E2F3a. NHFs were
transfected with the indicated siRNAs and infected with AdE7 after 24h. Lysates
were harvested at 24 hpi and immunoblots were performed. (B) Cells were
transfected and infected as in (A) and fixed and immunostained for yH2AX foci
localization at 24 hpi.
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Figure 3.14: E2Fl is responsible for HPV E7 induced MRll foci formation.(A) MR11 foci formation. NHFs were infected with AdCon or AdE7 and at 24 hpi
were fixed and immunostained for MRE11. (B) Western blot analysis of E2F1 and
E2F3a. NHFs were transfected with the indicated siRNAs and infected with AdE7
after 24h. Lysates were harvested at 24 hpi and imunoblots were performed. (C)Cells were transfected and infected as in (A) and fixed and immunostained forMR1110calization at 24 hpi.
DSB accumulation and yH2AX foci formation occur independent of ATM, NBSl, p53
and caspase activation.
Deregulated E2F1 activity by ectopic expression ofE2F1 or E7 induces ATM and
CHK2 activation, p53 phosphorylation, and subsequent apoptosis (23 , 268, 278 , 329). A
consequence of triggering the cellular apoptotic machinery is the activation of a caspase-
activated DNase, DFF40/CAD, which causes genomic DNA fragmentation associated
with apoptosis (350). To ensure that the DSBs that were accumulating in response to
deregulated E2F1 were not due to activation of the apoptotic program, we measured DSB
accumulation in cells that were not undergoing apoptosis.
Fibroblasts from patients with ataxia telangiectasia (AT), which lack a functional
A TM protein, are compromised in their ability to undergo E2F 1 or E7 induced apoptosis
(268 278) but can localize DNA damage response proteins into foci (218). Therefore, we
infected these cells with AdE2F1 and AdE7 and determined whether yH2AX foci form
and DSBs accumulate. We found that AT cells expressing either E2F1 or E7 were still
able to localize yH2AX to foci (Figure 3. 15A) similar to what is observed in normal
dermal fibroblasts (NDFs) albeit to slightly lower levels (Figure 3. 15B). Similarly, DSB
accumulation as determined by neutral comet assay also occurred (Figure 3. 16).
Cells from patients with nijmegen breakage syndrome (NBS) have defects in
DNA repair due to a mutation in the NBS 1 component of the MRN complex (108).
Similar to AT fibroblasts, NBS fibroblasts are also resistant to E2F1 or E7 induced
apoptosis (278). However, the ability of these cells to form yH2AX foci in response to
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Figure 3.15: Deregulated E2Fl-associated yH2AX foci occur independent of
ATM. NDF and AT cells were infected with AdCon, AdE2F1 or AdE7 and fixed
and immunostained for yH2AX 24 hpi (A). Cells were treated with etoposide as a
positive control. (B) Quantitation ofyH2AX positive cells.
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Treatment % Positive % Positive
91.8 :t 2. 86.3 :t 5.
AdCon 8 :t 0. 1 :t 1.
AdE2F1 32. 1 :t 3. 28.6 :t 3.
AdE7 34.5 :t 1. 29. 7:t 1.
Figure 3.16: Deregulated E2Fl results in DSBs independent of ATM.
NDFs and AT cells were infected with AdCon, AdE2F1 , or AdE7 and
analyzed for comet tail formation 24 hpi (A). Cells were treated with HzOz as a
positive control. (B) Quantitation of neutral comet assay.
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Figure 3.17: Deregulated E2Fl results in yH2AX foci formation independent of
NBS. NHFs and NBS cells were infected with AdCon
, AdE2F1 , or AdE7 andimmunostained for yH2AX 24 hpi (A). Cells were treated with etoposide as a
positive control. (B) Quantitation of cells positive for yH2AX foci formation.
Etoposide AdCon AdE2F1 AdE7
NDF
....
NBS
NDF NBS
Treatment % Positive % Positive
Etoposide 63.0 :t 2. 66. 7:t 1.
AdCon 5 :t 0. 9.4 :t 1.
AdE2F1 31.2 :t 1. 38.8 :t 2.
AdE7 30.0 :t 1.4 34.7:t 1.
Figure 3.18: Deregulated E2Fl leads to DSBs independent of NBS.
NHFs and NBS cells were infected with AdCon, AdE2F 1 , or AdE7 and were
harvested and analyzed by neutral comet assay 24 hpi (A). Cells were treated
with etoposide as a positive control. (B) Quantitation of cells positive for
comet tails.
deregulated E2F1 was intact (Figure 3. 17). Additionally, deregulated E2F1- associated
DSB accumulation was not affected in cells lacking functional NBS1 (Figure 3. 18).
In the absence ofp53 , E2F1-induced apoptosis is severely compromised in mouse
models (247, 262, 334) and cell cultue experiments (51 , 68, 131 , 173, 174, 221 , 259
269, 299, 357). Therefore, we determined whether yH2AX foci and DSBs accumulate
when p53 is depleted. NHFs were transfected with siRNAs designed to deplete p53
(sip53; Figue 3. 19A) and then infected with either AdE2F1 or AdE7. We found that
regardless of p53 levels, cells expressing either E2F1 or E7 stil localized yH2AX to
discrete foci (Figure 3.20A) and accumulated DSBs (Figue 3.20B). However, E2F1-
induced apoptosis was compromised when p53 was depleted (Figue 3. 19B).
It was also possible that E2F1-induced DSB accumulation occurs as a
consequence of activating or inducing the expression of caspases (223, 231 , 313).
Therefore, we tested whether yH2AX foci would form when E2F1 is deregulated and
caspase activity is inhibited. To test this possibility, NHFs were transfected with siRb and
treated with zV AD-fmk, a broad-spectrm caspase inhibitor. We found that although
zVAD-fmk treatment could prevent caspase 3 cleavage (Figure 3.21A), it did not affect
the percentage of cells positive for yH2AX foci when Rb was depleted (Figue 3.21B).
Together, these data indicate that E2F1-induced DSB accumulation is not the result 
activating the apoptotic program.
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Figure 3.19: Depletion of p53 reduces E2Fl induced apoptosis in NHFs.
(A) Western blot analysis for p53. Lysates were generated from NHFs
transfected with siCon, sip53A, or sip53B at 48h post transfection. (B)
Apoptosis assay. Cells were transfected as abover and then infected with
AdCon or AdE2F1 24h post transfection. Apoptosis assay was performed 72
hpi.
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Figure 3.20: Deregulated E2Fl-associated DSBs form independent of p53.
(A) Quantitation of yH2AX foci formation. NHFs were transfected with siCon
sip53A, or sip53B and at 24h post transfection, cells were infected with AdCon
AdE2F1 , or AdE7. Cells were fixed and immunostained for yH2AX 24 hpi. (B)
Quantitation of comet tail formation. Cells were transfected and infected as in (A)
and analyzed for DSBs by neutral comet assay.
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Figure 3.21: Rb depletion results in yH2AX foci independent of caspase
activation. (A) Western blot analysis for cleaved caspase 3. NHFs were
transfected with siRbA or siCon and immediately following transfection, treated
with zV AD-fmk or a DMSO control. Lysates were generated 72h post
transfection. (B) Quantitation of yH2AX-positive cells. At 48h post transfection
and zV AD-fmk treatment, cells were fixed, immunostained, and scored for
yH2AX foci formation.
Deregulated E2Fl-associated yH2AXfociform independent of MAD2 deregulation and
reactive oxygen species generation.
Microarray analysis identified the mitotic checkpoint protein, MA2 , as an E2F
target gene (270). More recently, it was shown that normal and transformed cells with
deregulated E2F1 have elevated levels of MAD2 (129). Given that aberrant MA2
activity leads to chromosomal iristability and aneuploidy, we asked whether MAD2
contributes to the DSB accumulation observed when E2F1 is deregulated. Three different
siRNAs effectively depleted MAD2 protein levels (Figure 3.22A). However, expression
of either E2F 1 or E7 in the MAD2 depleted cells resulted in the formation of y H2AX foci
(Figure 3.22B). These results indicate that MAD2 does not playa role in mediating E2F1
associated DSBs.
It has been suggested that expression of E2F 1 induces reactive oxygen species
(ROS) (324), although others have challenged this conclusion (268). However, ROS
generation could provide a potential mechanism for E2F1- induced DSB accumulation.
To test this hypothesis, we treated NHFs expressing E2F1 or E7 with N-acetylcysteine
(NAC), a ROS inhibitor. We found that NAC treatment had no effect on the percentage
of cells positive for yH2AX foci when E2F1 or E7 was expressed (Figure 3.23).
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Figure 3.22: MA2 does not contribute to yH2AX foci formation resulting
from deregulated E2Fl. (A) Western blot analysis. Lysates from NHFs
transfected with the indicated siRNAs were examined for MAD2 protein levels
48h later. Actin levels are shown as a loading control. (B). Quantitation ofyH2AX
positive cells. NHFs were transfected as above and were infected with the
indicated virus 24h after transfection. Cells were fixed and immunostained for
yH2AX foci 24hpi.
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Figure 3.23: ROS generation is not required for deregulated E2Fl-
associated yH2AX foci formation. NHFs were infected with AdE2F1
AdE7, or AdCon and immediately treated with NAC treated prior to fixation
and immunostaining for y H2AX foci.
E2Fl is not requiredfor c-MYC associated DSB accumulation.
Because c-MYC expression was shown to induce DSBs through ROS formation
(24 , 324, 337), AdMYC infected cells were treated with NAC and monitored for yH2AX
foci formation. Although NAC treatment did not change the percentage of cells positive
. for yH2AX foci when c-MYC was overexpressed (Figure 3.24), an approximate 50%
reduction in the number of foci per cell was observed, a result consistent with earlier
studies (337) (Figue 3.25). These results indicate that although ROS can produce DSBs
when c-MYC is overexpressed, there is an additional factor(s) that is activated by c-MYC
overexpression that leads to DSB accumulation. Because it was suggested that E2F1 is
required for c-MYC mediated apoptosis (189), we next determined ifE2F1 contributes to
yH2AX foci formation in cells overexpressing c-MYC by depleting E2F1 levels. We
found that siE2F 1 did not decrease the percentage of cells positive for y H2AX foci
formation nor the number of foci per cell when c-MYC was overexpressed (Figures 3.
and 3.25). Furthermore, siE2F1 and NAC treatment together did not reduce the number
of yH2AX foci induced by c-MYC overexpression beyond the effect of NAC treatment
alone. As expected, siE2F1 reduced the percentage of cells positive for yH2AX foci
formation when E7 was expressed, and NAC treatment in conjunction with siE2F1 had
no additional effect on the percentage of cells positive for yH2AX foci or the number of
foci per cell (Figure 3.24 and 3.25). Lastly, transfection with siRNAs directed against
E2F3a did not affect c-MYC or E7 induced yH2AX foci formation. Taken together, these
results show that ROS generation is not responsible for the DSB accumulation associated
with Rb inactivation or E2F1 overexpreSSlOn. In addition, E2F1 does not appear to
contribute to DSB accumulation associated with c-MYC overexpression.
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Figure 3.24: MYC-associated y H2AX foci form independent of deregulated
E2Fl. NHFs were transfected with the indicated siRNAs, infected with the
appropriate virus after 24 h, and immediately treated with NAC or a DMSO
control. At 24 hpi , cells were fixed and stained for yH2AX foci.
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AdMYC 83.20:t2. 15.15 :t 3.
77.22 :t 5. 28 :t 1.
81.94 :t 2. 15.36 :t 2.
78.33 :t 2.46 02 :t 1.
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Figure 3.25: MYC-associated DSBs are NAC sensitive but do not require E2Fl.(A) NHFs were transfected with the indicated siRNAs, infected with the appropriate
virus after 24 h, and immediately treated with NAC or a DMSO control. At 24 hpi
cells were fixed and stained for yH2AX foci. (B) The average number of foci per
cell from experiments carried out in triplicate is listed.
c. Discussion
Nuclear oncoproteins and DSB accumulation
In this study, we have shown that Rb inactivation and the resultant E2F1
deregulation results in DNA DSB accumulation. Previous work has shown that E7
expression in keratinocytes leads to DNA breaks as assessed by alkaline comet assay
(81). However, the alkaline comet assay detects both single-stranded and double-stranded
breaks (7, 242 , 245 , 308). We show by neutral comet assay that the breaks observed
when E7 is expressed are DSBs, and these DSBs are attrbuted to the ability of E7 to
inactivate Rb and subsequently deregulate E2F1.Moreover, the ability to induce DSB
accumulation is unique to E2F 1 among the E2F activator family members.
Another nuclear oncoprotein, c-MYC, has been shown to induce genomIc
instability through chromosomal abnormalities inappropriate replication, ROS
generation, and defective DNA repair (24, 92, 160, 190 , 209 , 324, 337). Although the
transcriptional and apoptotic relationship between E2F1 and c-MYC is complex, we did
not find a role for E2F1 in the formation of c-MYC associated DSBs (Figures 3.24 and
25). These results imply that in human cells, and potentially in human tumors, c-MYC
and E2F 1 associated DSBs are generated through distinct pathways.
Recently, elevated levels of MAD2 , a mitotic checkpoint protein, were found in
human tumors and were attibuted to it being an E2F target gene (129). Although we did
not find that MAD2 made a significant contribution to E2F I-associated DSB formation
(Figue 3.22B), the aneuploidy and genomic changes that were observed may be a
compound effect of the generation of continual DSBs when E2F1 is deregulated by Rb
inactivation as well as MAD2 hyper-activation.
The question remains as to how deregulated E2F1 results in DSBs. One
possibility is that deregulated E2F 1 may prevent the timely repair of DSBs that arise
endogenously, thereby allowing these breaks to persist. In support of this idea, the
number of yH2AX foci, and presumably 'DSBs, is relatively low in E7 or E2F1
expressing cells (Figue 3.25B). These low levels ofyH2AX may explain why it was not
detected in AdE2F1-infected NHFs by immunoblotting (268). Alternatively, deregulated
E2F 1 may destabilize replication forks, causing them to stall and collapse, perhaps a
result of imbalances in the expression of E2F 1 target gene products involved in dNTP
synthesis or DNA replication. However, replication fork collapse is usually signaled by
theATR and CHK1 kinases (286) and we have not yet found a role for these kinases in
deregulated E2F1 signaling (278). In addition, the percentage of cells positive for yH2AX
foci was not substantially different in serum starved or cycling cells expressing E2F1 or
E7 (data not shown), suggesting that S phase entry is not needed for E2F1 associated
DSBs to occur. Both of these potential mechanisms need to be fully investigated.
Given that the primary kinase believed to phosphorylate H2AX is ATM (34), our
findings that Rb inactivation and E2F1 deregulation lead to yH2AX foci formation in
cells lacking functional A TM suggest that there may be some redundancy with another
PI-KK family member. There is evidence that ATR may phosphorylate H2AX in some
contexts (118 , 345). However, most recent data suggest that DNA-PK is the more likely
candidate in human cells (248 , 315). Although, we have not looked at A TR activation in
AT fibroblasts, we did not observe A TR activation following E2F 1 deregulation in
normal human fibroblasts (278), indicating that perhaps DNA-PK is the kinase that
phosphorylates H2AX in AT cells when E2F1 is deregulated.
Relationship between nuclear oncoprotein-induced DSBs and apoptosis
Of the activator E2Fs, ectopic expreSSIOn of only E2F1 effciently induces
apoptosis despite the ability of all three proteins to potently induce S phase progression in
rodent cells (68 , 153 , 174). These observations imply that the strong signal of deregulated
proliferation caused by expression of these E2Fs must not be suffcient for a cell to
undergo apoptosis. Based on our observations
, we suggest that the ability to signal
apoptosis by E2F1 , or c-MYC for that matter, may have more to do with DSB
accumulation than with the ability to promote S phase progression. Additionally, it
appears that E2F1 overexpression in normal human fibroblasts may actually signal a G
checkpoint that involves the NBS1 , 53BP1 , p53 , and p21 proteins, and protects against
apoptosis in human cells (98 , 201). Because E2F1 expression also signals p53-dependent
senescence (75 , 285), it remains to be determined whether this checkpoint contributes to
cell senescence. It is interesting to note that this cell cycle checkpoint does not seem to
occur in rodent cells (28); rather rodent cells enter S phase and undergo apoptosis (68;
153, 174). Therefore, it appears that in human cells, the initial response to E2F1
associated DSBs is to signal a checkpoint, but if the DSBs persist, apoptosis eventually
predominates.
Inactivation of Rb and deregulation of E2F in cancer
Inactivation of the Rb tumor suppressor occurs in many cancers, and ,the
consequence of loss of Rb for transformation has largely been attibuted to derepression
of cell cycle progression. However, in this study, we have shown that another
consequence of Rb inactivation in normal cells is the accumulation of DSBs due to
deregulated E2F 1. These, like other DSBs, could potentially manifest as genomic
rearrangements, chromosomal abnormalities, DNA repair errors, and aneuploidy. Several
lines of evidence suggest that Rb inactivation and deregulated E2F 1 significantly
contribute to the development of tumors. First, crossing E2F rl- mice with Rb +1- mice
reduces and delays the onset of pituitary and thyroid tumors found in mice (361). A
similar decrease in tumors was observed in another mouse model where a fragment of the
SV 40 large T antigen that inactivates Rb is expressed in the brain of an E2F r
l- mouse
(247). Furhermore, it has been suggested that immunohistochemical staining for E2F1
can be used as a prognostic marker for human breast carcinoma because the staining for
E2F1 becomes more intense as cancers progress (364). 'Based on our findings in normal
cells, we speculate that the relationship between deregulated E2F1 and cell
transformation is not solely due to derepression of Rb-mediated proliferation control, but
also due to the accumulation of DSBs when E2F 1 is deregulated.
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CHAPTER IV:
MODULATING RB AND E2F!
FACILITATES THE MANIPULATION
OF DNA DOUBLE STRAND BREAK
LEVELS IN CANCER CELLS AND
TUMORS
Introduction
Although it is unclear which cellular factor(s) is responsible for the genetic
instability associated with initiating and sustaining cell transformation, it is known that
virtally all cancers have mutations that inactivate the Rb-mediated growth control
pathway (115, 234, 295 , 301). The mechanism of Rb inactivation varies between
different tumors and may include mutation or deletion of the Rb locus, overexpression
and activation of oncogenes that regulate Rb activity, such as cyclin D (16, 71 , 106 307),
loss of cdk inhibitors, such as p16INK4 (158 , 281), or inactivation and/or degradation of
Rb by viral oncoproteins from small DNA tumor viruses (302). Given that cancer cells
inactivate the Rb pathway and that Rb inactivation results in DNA DSB accumulation in
normal cells , we hypothesized that cancer cells may have elevated basal levels of E2F1-
associated yH2AX foci.
In addition to Rb, c-MYC also regulates E2F1 , albeit through different
mechanisms. Recently, c-MYC trans activated miRNAs were identified that limit E2F1
protein expression (239), despite E2F1 being a transcriptional target of c-MYC (93 , 187).
We speculated that a reason that E2F1 levels are so tightly regulated may be due to its
ability to promote DSB accumulation when deregulated. Therefore, we examined
whether DSBs accumulate when E2F1 is deregulated by inhibiting the miRNAs that limit
E2F 1 translation.
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Results
Endogenous E2F activity contributes to DSB accumulation in cancer cell lines when Rb
is inactivated
Many tumors have Rb inactivating mutations, leading to the deregulation of
E2F!. Because we found that deregulated E2F1 results in DSB accumulation in normal
cells, we speculated that cancer cells that have mutated Rb might have endogenous DSBs
arising from deregulated E2F1 activity. To test this hypothesis, the osteosarcoma cell
line, SaOS2 , which has Rb inactivated, was examined for basal levels of DSBs and
compared to U20S cells
, which have p16INK4 inactivated but otherwise retain wildtye
Rb. We immunostained both cell lines for endogenous yH2AX foci and found that
SaOS2 , but not U20S , cells stained strongly for yH2AX foci (Figure 4. 1B). When SaOS2
cells were transfected with siE2F1 (Figure 4. 1A), an approximate 50% reduction in the
percentage ofyH2AX positive cells was observed (Figure 4. 1B and C).
Given that Rb is wildtype in U20S cells, we speculated that inactivating Rb in
these cells might increase the basal levels of yH2AX foci. Transfection of U20S cells
with siRbA resulted in an approximate 6- fold increase in the percentage of cells with
basal yH2AX foci (Figue 4.2). These DSB-associated foci were also observed when E7
was expressed in U20S cells (Figure 4.3). The accumulation of yH2AX foci induced by
HPV E7 expression was attibuted to deregulated E2F 1 because foci formation was
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Figure 4. 1: E2Fl-associated DSBs are present in an Rb mutant cancer cell line.
(A) Western blot analysis of E2F1 from extracts of SaOS2 and U20S cells
transfected with siE2F1or siCon 48 h post transfection. (B) SaOS2 or U20S cells
were transfected with siE2F1 or siCon and at 48 h, were fixed and immunostained
for yH2AX foci. (C) Quantitation ofyH2AX positive cells.
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Figure 4.2: Rb depletion in an Rb wildtype cancer cell line leads to y H2AX
foci formation. (A) U20S cells were transfected with siRbA or siCon and at
48 h post transfection, were fixed and immunostained for yH2AX foci. (B)
Quantitation ofyH2AX foci.
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Figure 4.3: E2Fl is responsible for yH2AX foci formation induced by Rb
inactivation in an Rb wildtype cancer cell line. U20S cells were transfected
with siE2F1 , siE2F3a, or siCon and infected with AdE7 or AdCon. At 24hpi, cells
were fixed and immunostained for yH2AX foci.
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sensitive to transfection with siE2F1 , but not siRNAs directed against E2F3a (Figure
3).
To determine if Rb inactivation and resulting E2F1 deregulation occurs in cancer
cell lines derived from other tumors, we screened several lines and looked at basal
yH2AX foci levels and the influence of modulating Rb and E2F1 activity. We found
elevated levels of y H2AX positive cells in two other Rb mutant cell lines, similar to our
observations in SaOS2 cells (Figue 4.4). Furhermore, the levels ofyH2AX foci positive
DU145 (prostate carcinoma) and C33A (cervical carcinoma) were reduced by
approximately 50% when siE2F1 was transfected (Figure 4.4). Moreover
, MCF7 (breast
carcinoma) and H1299 (non-small cell lung carcinoma) cells
, which are Rb wildtype but
have p 16ink4 inactivated, and the HPV positive HeLa ( cervical carcinoma) cells, all have
low basal levels of yH2AX foci positive cells, similar to U20S cells. Transfection with
siRb in all of these cell lines resulted in an increase in yH2AX levels (Figure 4.5).
Expression of HPV E7 in MCF7 cells induced an accumulation of yH2AX positive cells
that was sensitive to transfection with siE2F1 (Figure 4.6). Taken together, these results
suggest that Rb inactivation and the resultant E2F 1 deregulation increases the occurence
of DSBs in cancer cell lines.
Inhibiting miRNAs that regulate E2Fl protein expression results in DNA DSB
accumulation in normal human fibroblasts and cancer cell lines.
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Figure 4.4: Rb mutant cancer cell lines accumulate E2Fl-associated yH2AX
foci. Three cancer cell ' lines that have Rb mutations were transfected with a
control siRNA or two different siRNAs that target E2F 1. After 48h, cells were
fixed and immunostained for yH2AX.
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Figure 4.5: Inactivation of Rb in cancer cell lines with Rb pathway mutations
results in elevated levels of y H2AX positive cells. Three cancer cell lines that have
p16 k4 inactivated and an HPV positive cell line were transfected with either a
control siRNA or two different siRNAs that target Rb. After 48h, cells were fixed
and immunostained for yH2AX.
U20S MCF7 H1299 HeLa
p16 ink4 inactivated H PV E7 expressed
-- 60
!! 50
w 30
siCon
siE2F1 A
siE2F1 C
107
Figure 4.6: E7 inactivation of Rb results in an accumulation of y H2AX
foci that are associated with deregulated E2FI. U20S and MCF7 cancer
cells were transfected with either siCon, siE2F1A, or siE2F1C. After 24h
transfected cells were infected with AdE7. At 24 hpi, cells were fixed and
immunostained for y H2AX.
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Aberrant expression of miRNAs has recently been described in cancers. Because
two c-MYC regulated miRNAs miR-17-5p and miR-20a have been shown to reduce
E2F1 expression (239), we asked whether inhibition of these miRNAs would result in
DSB accumulation. 2' - O-methyl oligoribonuc1eotides that are antisense to either of the
miRNA sequences (239) or antisense to the luciferase gene product (141) were
transfected into NDFs. After 24h, elevated E2F1levels were observed in cells transfected
with the 2' 0-methyl RNAs that target miR-17- 5p or miR-20a (Figure 4.7A), consistent
with previous observations (239). Additionally, inibition of either miRNAs resulted in
an approximate 4-5 fold increase in yH2AX foci formation (Figue 4.7B and 4.7C) and
led to DNA DSB accumulation as observed by neutral comet assays (Figure 4.7D).
We then asked whether transfection of these antisense 2' - 0-methy1 RNAs would
lead to increased DSBs in cancer cells. Indeed, yH2AX foci were observed in HeLa
(Figure 4.8) and U20S transfected cells, with maximum levels observed between 18-24h
post transfection (Figue 4.9).
Inhibitng miRNAs that regulate E2F protein expression results in decreased BrdU
incorporation.
Recently, our laboratory has defined a Gj-S checkpoint that is elicited in response
to deregulated E2F1 by ectopic expression (98). Given that DSB accumulation resulted
from deregulated E2F1 expression via inhibition of miR-17-5p and miR-20a we asked
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Figure 4.7: 2- O-methyl inhibition of miR-17-5p and miR-20a leads to DSB
accumulation in normal human cells. NHFs were transfected with 2' 0-methyl
RNAs that are antisense to miR-17- 5p (17- 5), miR-20a (20a), or the luciferase (luc)
transcript as a control. (A) Western blot analysis. Lysates of transfected cells were
analyzed for E2F 1 protein levels 24h post transfection. Actin levels are shown as 
control. (B) yH2AX foci formation. Transfected cells were fixed and immunostained
for yH2AX 24h after transfection. (C) Quantitation of yH2AX foci. Cells were
scored 24h post transfection. (D) Quantitation of neutral comet assay. At 24h post
transfection, cells were analyzed for comet tail formation.
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Figure 4.8: 2' O-methyl inhibition of miR-17-5p and miR-20a results in yH2AX
foci formation in a cancer cell line. HeLa cells were transfected with 2' -O-methyl
RNAs that are antisense to miR-17- 5p, miR-20a, or the luciferase transcript as a
control. (A) Western blot analysis. Lysates of transfected cells were analyzed for
E2F1 protein levels 24h post transfection. Actin levels are shown as a control. (B)
yH2AX foci formation. Transfected cells were fixed and immunostained for yH2AX
24h after transfection. (C) Quantitation of yH2AX foci. Cells were scored 24h post
transfection.
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Figure 4.9: Maximum yH2AX foci accumulation resulting from 
methyl inhibition of miR-17-5p and miR-20a occurs at 24h post
transfection. Two cancer cell lines, U20S and HeLa, were transfected with
0-methyl RNAs that inhibit miR-17- 5p and miR-20a and were fixed and
immunostained for y H2AX foci at the indicated times post transfection.
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whether the Gj-S phase transition would be affected. To address this question, growth
media containing serum and BrdU was added to serum-starved NHFs transfected with 2'
O-methyl RNAs that are antisense to miR-17-5p, miR-20a or luciferase. We found that
the population of BrdU positive cells was reduced when cells were transfected with 2' 
methyl RNAs that are antisense to miR-17-5p or miR-20a compared to cells that were
transfected with the 2' -O-methyl RNAs that is antisense to luciferase or to mock-
transfected cells (Figure 4. 10). As a control, the majority of mock-transfected cells that
were maintained in serum-starVation media did not incorporate BrdU. These data suggest
that inhibition of miRNAs that regulate E2F 1 levels prevents Gj-S phase transition and
raises the possibility that a G checkpoint may be activated.
Breast tissue organ cultures are viable and susceptible to infection with recombinant
adenovirus.
Most, if not all, solid tumors have mutations in the Rb pathway. In the case of
breast tumors, mutations in Rb are rarely found and the Rb pathway lesion is typically an
inactivation of the p 16ink4 locus or an amplification of cyclin D 1. Based on our studies in
cancer cell lines, we wanted to determine whether we could manipulate the occurrence of
DSBs in human tissue by inactivating Rb. To address this question, we developed a
system to maintain and infect tissue organ cultues with recombinant adenovirus. Normal
human breast tissue was obtained from a reduction mammoplasty and cut into fragments
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Figure 4.10: 2' O-methyl inhibition of miR-17-5p and miR-20a reduces S
phase entry. NDFs were serum starved in DMEM supplemented with 0. 10% FBS
and then transfected with 2' 0-methyl RNAs antisense to miR-17-5p, miR-20a
luciferase. Immediately following transfection, complete media containing 10 /-M
BrdU was added to the cells. The cells were then fixed and immunostained for
BrdU at the indicated times post transfection.
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of approximately 3mm . They were maintained in culture for 24 or 48 hours and then
fixed, sectioned, and stained with hematoxylin and eosin (H&E) (Figue 4. 11). At 24h
there was no difference histologically in the morphology of the cultues compared to
samples that were fixed immediately. By 48h, we did observe a slight mitogenic effect in
the ductal cells of the tissue, observed as an increase in size of the nucleoli and basophilia
of the cytoplasm (Figue 4. 11). Although there may have been some growth stimulation
in the ducts by 48h, we found that the breast tissue was viable and could be maintained in
cultue for (at least) 48h.
We next asked whether the excised tissue could be infected with recombinant
adenovirus in tissue culture. The harvested tissue was transduced with AdGFP and
incubated for 48h prior to fixation. Immunohistochemistry was then performed on the
tissue sections. We did not observe any obvious changes in morphology due to the
recombinant adenovirus infection and GFP was detected in a subset of the epithelial cells
(Figure 4. 12) indicating that the cells susceptible to infection in an organ cultue are the
cells in which breast carcinoma arises.
HPV E7 expression correlates with increased levels of yH2AX in a breast tumor.
Given that we could maintain and infect normal breast tissue, we wanted to
determine if we could cultue tissue ' from a breast tumor. Tissue was obtained from a
mastectomy of a high-grade tumor, cut into approximately 3mm3 fragments, and
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Figure 4.11: Slices of normal human breast tissue can be maintained in
culture for at least 48 hours. Hemotoxylin and eosin staining of sections from
breast tissue organ cultures that were fixed after 24 (left) or 48 (right) hours in
culture. Samples of ductal epithelial cells are indicated with red arrows and the
surrounding stromal tissue is indicated with blue arrows.
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Figure 4.12: Organ cultures of human breast tissue can be infected with
recombinant adenovirus. Immunohistochemistr for GFP expression was
performed on sections of normal breast organ cultures to detect cells that were
infected with AdGFP.
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Figure 4.13: Slices of a human breast tumor can be maintained in culture for
at least 48 hours. A high grade breast tumor procured from a mastectomy was
sectioned and either uninfected (top) or infected with Ad-GFP (middle) or Ad-E7-
GFP (bottom). After 48h, the organ cultues were fixed, sectioned and stained with
hemotoxylin and eosin.
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cultured for 48h prior to fixation. To detennine if the tumor organ cultue could be
infected with recombinant adenovirus
, a subset of the excised tissue was infected with
AdGFP. H&E staining indicated that the tumor fragments could be maintained for (at
least) 48h and that infection with the recombinant adenovirus did not alter the
morphology of the tuor tissue (Figure 4. 13). Additionally, sections were co-
immunostained for GFP and yH2AX levels. For technical reasons, GFP could not be
detected directly and needed to be detected via immunostaining. We found that although
the tumor tissue was susceptible to infection with AdGFP (Figure 4. 15), there were low
levels of yH2AX in the uninfected and AdGFP infected tumor tissue (Figues 4. 14 and
15).
We next wanted to determine if we could modulate the level ofy H2AX in the
tumor sample by inactivating Rb. To address this question, the excised tissue was
infected with an adenovirus encoding both HPV E7 and GFP (Ad-E7-GFP). We found
that most of the GFP positive cells were also yH2AX positive (yellow arrows), although
there were low levels of cells that were uninfected and y H2AX positive ( orange arrows)
and other cells that were infected and negative for yH2AX (green arrows) (Figure 4. 16).
These results suggest that the levels ofyH2AX, and potentially DSBs, may be altered in a
tumor by manipulating the Rb status of the cells in the tumor.
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Figure 4.14: Low levels of yH2AX positive cells in a breast tumor.
Uninfected slices of a high grade breast tumor were cultured for 48h and co-
immunostained for levels of DSBs (top: yH2AX; blue) and as a control for
infection with recombinant adenovirus (middle: GFP; red). The merged image
(bottom) indicates select cells that are yH2AX positive and GFP negative
( orange arrows).
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Figure 4.15: Expression of GFP does not increase levels of y H2AX positive
cells in a breast tumor. Slices from a high-grade breast tumor were infected
with Ad-GFP, cultued for 48h, and co-immunostained for levels of DSBs (top:yH2AX; blue) and infection (middle: GFP; red) and
. The merged images(bottom) indicate GFP positive
, yH2AX negative cells (green arrows), GFP
positive, yH2AX positive cells (yellow arrows), and yH2AX positive GFPnegative cells (orange arrows).
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Figure 4.16: Increased yH2AX staining in tumor slices infected withHPV-E7-GFP. Slices from a high-grade breast tumor were infected with
Ad-E7-GFP, cultured for 48h
, and co-immunostained for levels of DSBs(top: yH2AX; blue) and infection (middle: GFP; red). The merged images
(bottom) indicate GFP positive
, yH2AX negative cells (green arrows), GFP
positive, yH2AX positive cells (yellow arrows), and yH2AX positive
, GFP
negative cells (orange arrows).
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Discussion
Inactivation of Rb and p53 in cancer
The fuctional loss of Rb is an important event in the progression of a tumor cell
and it has been thought that mutations that inactivate the Rb pathway are functionally
equivalent. Although it is true that the overall effect of any Rb pathway mutation is to
promote inappropriate cell cycle entr by E2F deregulation, we have shown here that the
different mutations within this pathway have substantially different levels of E2F1-
associated DSBs. In cancer cells that have Rb mutations, elevated basal levels of E2F1-
associated yH2AX foci are observed (Figue 4.4). However, in cancer cells that either
have p 16ink4 inactivated or express HPV low basal levels of E2F I-associated y H2AX
foci are observed. In these cancer cells, wildtype Rb is retained and treatment of these
cell lines with siRb increased the percentage of cells positive for DSBs (Figue 4. 5).
These results suggest that there must be some residual Rb activity in these cells, which
once inactivated, permits E2F I-associated DSBs accumulation.
It has been thought that the p53 pathway is mutated in cancers as a way to bypass
the cellular response to inappropriate proliferation signals. However, the results presented
here offer another explanation as to why p53 mutations are so critical to tumor formation
in cells lacking functional Rb. We suggest that in order for a cell to surive the
continuous assault of DSBs associated with Rb inactivation and E2F 1 deregulation, it
may be necessary for cells to inactivate p53 to bypass DNA damage checkpoint signaling
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and subsequent apoptosis. If this is true
, then these results also shed light on why 
inactivation seems to correlate with p53 mutations in cancer cells, like SaOS2 cells, and
why this correlation is not always observed in cancer cells that are 
Rb wildtye but have
mutations in the Rb pathway, like U20S cells.
E2F I-associated DSBs and cancer therapy
The idea that a patient' s cancer may vary markedly from another patient
, and that
each patient will respond differently to treatment has long been recognized. To combat
this issue, a move toward individualized patient therapy is underway with the idea that
the customized treatment wil lead to a better patient prognosis with less toxicity. Based
on our observations, we suggest that there may be potential to alter the cell death
response of normal and tumor cells by modulating the level of DSBs via manipulation of
Rb/E2F 1 activity. For instance
, cancer cells that have p 16ink4 silencing mutations, but
tetain wildtye Rb and p53 may be more sensitive to chemotherapy or radiation
treatment if the background level of DSBs, and subsequent death or senescence response
is elevated by deregulating E2F 1 via Rb inactivation. Several lines of evidence suggest
that this approach may be worth pursuing. First
, E2F1 is stabilized via phosphorylation
and acetylation in response to DNA damaging agents (139, 142, 192, 196, 255, 314).
Additionally, melanoma cells that ectopically express E2F1 are more sensitive to
topoisomerase inhibitors (76). Furthermore, the converse is tre; chemotherapy-
induced apoptosis is reduced in cells where E2F1 levels are depleted (343 , 344). The
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preliminary observations that we have showing that breast tumor tissue can be infected
with recombinant adenovirus (Figues 4. 12 and 4. 15) and that , the level of DSBs
correlates with Rb inactivation (Figure 4. 16) raises the possibility that these studies may
be pursued in organ cultures.
Another conceivable benefit to using Rb/E2F 1 status as a means to sensitize
tumor cells to cell death is the potential for reduced toxicity to the patient. The unpleasant
side effects of chemotherapy are caused by the kiling of normal cells within the patient.
The miRNA data (Figues 4.7 and 4.8) suggest that small changes in E2F1 levels can
elicit DSBs. Therefore, it is plausible that by slightly increasing E2F1 activity, the
required dosage of chemotherapeutic may be reduced enough that the levels of DSBs in
normal cells may be tolerated and repaired, thereby reducing toxicity to the patient.
Alternatively, there may be a benefit to decreasing E2F 1 for protection of normal cells in
some contexts.
Putative role for c-MYC regulatedmiRNAs in regulating E2Fl activity
The observation that c-MYC transactivates E2Fl message (93, 187) and then
inhibits its protein expression through miRNAs (239), highlights the importance of strict
control ofE2F1. It has been known that there is a delay between E2F1 mRNA expression
in early-mid G and the accumulation ofE2F1 protein in late G . Although the reason for
the miRNA- mediated delay of E2F1 protein expression is still unclear, one hypothesis
which is supported by an E Myc transgenic mouse that overexpresses the miRNAs, is
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that expression of miR-17-5p and miR-20a decrease apoptotic signaling (122). Based on
our data, we suggest another, yet complimentary hypothesis where the miRNAs strictly
control the temporal expression ofE2F1 in normal cells until a period in G when the cell
is equipped to handle increased E2F1 activity. In our model
, when miR-17- 5p or miR-20a
is inhibited, the cell' s initial response to deregulated E2F1 is to prevent S phase entr
(Figue 4. 10). Having recently described a G checkpoint that is initially activated
following ectopic expression ofE2F1 , and which eventually succumbs to apoptosis (98),
the question remains whether inhibition of the miRNAs will also have these effects.
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A. DSB accumulation and apoptosis following Rb inactivation is unique to E2Fl
The link between Rb inactivation, deregulated E2F1 , and p53-induced apoptosis
is well established (4, 173 , 174, 247, 262, 269, 299, 334, 357). However, the reason that
deregulated E2F 1 , but not the other activator E2F family members, results in apoptosis
has been unclear. It has been shown that all three activator E2F proteins transactivate
p14AR/p19Arf expression (18 , 146 249 , 273), indicating that this activity is not unique to
E2F 1 , and suggesting that it may not be the pathway to apoptosis. Consistent with this
observation, we have found that although p 19Arf /Mdm2 may contribute to p53 protein
accumulation, this pathway is not required for E2F1-induced apoptosis (Figues 3. 1 and
2; (277)). In agreement with our in vitro observations, data from mouse models have
also demonstrated that p14ARF/p19Arf is not required for apoptosis (283 328 335). Taken
together, it is clear that deregulated E2F1 must generate an additional signal(s) that
results in apoptosis. The data from this thesis have identified that Rb inactivation, and the
resultant deregulated E2F 1 , leads to DNA DSB accumulation. This activity is unique to
E2F1 , because deregulation of other E2F family members does not result in DSB
accumulation (Figure 3. 13). We showed that these E2F1-associated DSBs are not
attbuted to activation of apoptotic signaling because they form in cells that are
compromised in their ability to undergo apoptosis by lacking fuctional ATM (Figures
15 and 3. 16), NBS1 (Figures 3. 17 and 3. 18), or p53 (Figure 3.20) or by inhibiting
caspase activation (Figure 3.21). Additional data from our laboratory has shown that
deregulated E2F1 specifically induces p53 phosphorylation at serine 20, which is an
128
event that is coincident with apoptosis (278). Moreover, deregulated E2F1 specifically
induces CHK2 message and protein activation, which is required for phosphorylation of
p53 on serine 20 (278). Because CHK2 activation and p53 phosphorylation on serine 20
are E2F I-specific events upstream of apoptosis, and because the ability to accumulate
DSBs is unique to E2F 1 , we believe that E2F I-associated DSBs is the propert of E2F 1
that makes it toxic to cells when it is deregulated.
B. Nuclear oncoproteins, DSB accumulation, and apoptosis
Like E2F1 , many tumors have deregulated c:.MYC expression. The deregulation
of c-MYC has been attibuted to its growth and proliferating-promoting activities, yet it
has also been found to induce genomic instability via a variety of mechanisms including
generation of reactive oxygen species (ROS) (24, 92 , 160, 190 209 324 337). Although
ROS does contribute to c-MYC-associated DSBs (Figure 3.25; (268 , 324, 337)), we do
not find a role for ROS in the generation of E2F I-associated DSBs (Figue 3.23).
Currently, there is conflict in the literature regarding the requirement of E2F1 for
MYC mediated apoptosis (19, 189). Our findings have shown that although deregulated
E2F1 , like c-MYC , results in DNA DSB accumulation, the DSBs are generated through
distinct pathways. Because we believe that DSB accumulation precedes apoptosis, we
suggest that c-MYC induced apoptosis ,does not require E2F1. Consistent with this idea
MYC transactivates the miR-17-92 locus, resulting in the production of miRNAs that
inhibit E2F1 protein expression (239). These observations suggest that cells with
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amplified c-MYC activity, wil have down-regulated E2F1 protein levels and therefore
reduced E2F1-associated DSBs and E2F1-mediated apoptosis.
C. Deregulated E2Fl activates a GI /S checkpoint in human cells
Ectopically expressing any of the three activator E2F proteins in quiescent rodent
cells, stimulates entr into S phase (68, 153 , 174). However, ectopic expression of only
E2F1 effciently induces apoptosis, implying that an inappropriate proliferation signal is
not sufficient to induce apoptosis. Based on our findings, we suggest that the unique
propert of E2F 1 that stimulates apoptosis is its ability to induce DSB accumulation.
Recent data from our laboratory has indicated that prior to activation of apoptotic
signaling, deregulated E2F 1 in normal human cells signals a G checkpoint that involves
NBS1 , 53BP1 , p53 and p21 (98). This checkpoint appears to protect human cells from
apoptosis, because abrogation of the checkpoint results in an increased rate and level of
apoptosis. Consistent with these observations
, our findings that inhibition of miR-17-
and miR-20a results in reduced BrdU incorporation (Figue 4. 10), suggest that even small
changes in E2F 1 levels can lead to a G checkpoint. Furhermore, the data suggest that
the timing of E2F1 activity in a cell is crucial: It has been known that E2F1 message
increases early in G , but that the protein levels do not accumulate until late G\. We
speculate that the miRNAs, which are also expressed early in G , function to limit E2F1
until a time during the cell cycle when cells are prepared to deal with the consequences of
activating E2F1 , namely the potential for E2F1-associated DSBs. By inhibiting miR-17-
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5p andmiR-20a we disrupted the timing and levels of E2F1
, thereby activating the G)
checkpoint.
Interestingly, although yH2AX foci form following Rb inactivation in rodent
cells, a G checkpoint is not elicited (28). Rather, rodent cells enter S phase and undergo
apoptosis (68, 153 , 174). Based on our model
, it is provocative to suggest that the miR-
17-92 locus may not be present in rodent fibroblasts
, which is not yet known. Presence of
the locus would indicate that the signaling response to Rb inactivation and E2F1
deregulation is different between humans and rodents. However
, should the miR- 17-
locus be missing in rodent cells, it will be interesting to determine whether rodent cells
behave like human cells when miR-17-5p or miR-20a is expressed.
D. E2F! as a tumor suppressor and an oncogene
The stringent regulation of E2F1 levels, as demonstrated by the c-MYC/E2F1
relationship and the accumulation of DSBs when it is deregulated, underscores its
importance in maintaining cellular homeostasis. Based on our observations
, we suggest a
model where E2F1 expression is temporally regulated until the cell is prepared to cope
with the consequence of activating E2F1 , namely E2F1-associated DSBs. In this model
the inappropriate activation of E2F 1 in normal cells serves as a tumor suppressor function
by activatingp53 and initiating a G) checkpoint. We propose that in a nonnal cell cycle
either the number of DSBs associated with E2F1 is below the threshold to initiate
apoptosis or a G checkpoint, or alternatively, a cellular factor is present that suppresses
! '
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the mechanism for E2F1-associated DSBs. Whatever the mechanism
, temporal mIS-
expression ofE2F1 by inhibition ofmiR-17-5p or miR-20a or premature derepression of
E2F 1 by Rb inactivation, causes DSB accumulation and activation of a G checkpoint.
This G checkpoint provides time for the cell to tr and initiate DNA repair, which, if
successful, allows the cell to continue to proliferate or if unsuccessful
, the cell may
succumb to apoptosis. Although our laboratory has shown that deregulated E2F 1 can
initiate a G checkpoint (98), whether E2F 1 can signal checkpoints in other phases of the
cell cycle is not yet known.
The cellular signal that tei-inates checkpoint signaling and initiates apoptosis
signaling is not yet known. However, it was recently shown that A TM is acti,:ated by
approximately 8 DSBs (12 , 35), whereas 19 DSBs is sufficient to activate CHK2 (35).
Given that Atm can be activated by deregulated E2F2 in human cells
, but that CHK2
activation, and subsequent apoptosis, are specific events following E2F1 deregulation
(278), it is conceivable that the activation of CHK2 and 
subsequent phosphorylation of
p53 on serine 20 are the cellular signals that terminate checkpoint signaling and initiate
apoptosis. However, CHK2 activation and p53 phosphorylation on serine 20 are observed
by 24h following E2F1 deregulation (278), and significant apoptosis is not detected until
72-96h (98), indicating that there must be an additional signal(s) to terminate checkpoint
signaling and activate apoptosis. Because the DNA damage foci contain a multitude 
proteins, one possibility is that a subset of checkpoint-associated proteins may be
released from the foci, or otherwise inhibited, and the loss of this maintenance signal
commences apoptosis signaling. A potential candidate is protein phosphatase 2A (PP2A),
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which has been shown to dephosphorylate yH2AX in order to facilitate DNA DSB repair
(53 , 232). When the catalytic subunit of PP2A was inhibited, yH2AX foci persist and
repair is not effcient (53). Whether E2F1 affects PP2A function has not yet been
determined.
In addition to acutely ablating Rb function
, we have found that Rb mutations in
cancer cells result in E2F I-associated DSBs. We suggest that the level of E2F 1-
associated DSBs resulting from Rb mutations necessitates a p53 mutation to circumvent
the continuous assault of E2F I-associated DSBs (Figue 5. 1). However, in cells with
wildtye but Rb pathway mutations, the basal level of E2F1-associated DSBs is low
enough that any mutation in the p53 pathway is suffcient to bypass p53-mediated
apoptosis. In this scenario, deregulated E2F1 acts as an oncogene to selectively pressure
cells to mutate the p53 pathway, thereby circumventing p53 apoptosis signaling. Our
model, therefore, suggests that an early event in the establishment of an emerging tumor
cells is Rb inactivation because that cell would need deregulated E2F1 to inactivate p53
function and generate DSBs to facilitate additional mutations. Consistent with this idea
, it
was suggested that p53 mutations arise as a result of constitutively active DNA damage
signaling, in particular CHK2 activation (116), which is an event that we find occurs as a
result of deregulated E2F1 (278). This idea raises the possibility that deregulated E2F1
could function as a component of the "mutator phenotype." Although this hypothesis
remains untested, it seems plausible based on the observations that HPV E7 expression
and adenoviral E1A expression lead to yH2AX foci formation, ATM activation, and
genomic instability (30, 37 , 61 , 79 , 81 , 347). Although we have shown that yH2AX foci
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formation, ATM activation, and DNA DSBs are E2F1-associated events in E7 expressing
cells, whether E2F1 plays a role in the E1A-induced events is still unown.
An extension of our model is that the continual generation of DSBs may
eventually be detrimental to the emerging tumor cell. In concordance with this idea, it
was reported that activated CHK2 and yH2AX levels are highest in Ta and T1 stage
tumors, and are reduced but stil present in T2- T 4 stage tumors, suggesting that it may be
beneficial for an emerging tumor cell to disable DNA damage signaling in later stage
tumors (15, 113). This idea is also supported by the observation that early tumors are
karyotypically heterogeneous whereas this genetic plasticity is not found in homogeneous
and chromosomally stable late stage tumors and tumor lines that have been adapted to
tissue culture (198). Given that yH2AX foci and activated CHK2 are events we observe
following deregulated E2F1 , it follows that E2F1-associated DNA DSB accumulation
may be dampened as tumors progress. It is possible that the cell gains a mutation in the
genes involved in the mechanism of E2F1 associated DSBs. Additionally, amplification
of the miR-17-92 locus in tumors could result in decreased E2F1 activity. Because we can
still detect E2F1-induced yH2AX foci in SaOS2 and other Rb mutant lines (Figure 4.4), it
is also possible that DNA repair is extremely efficient in these cells.
E. Possible mechanisms of E2Fl-induced DSB accumulation
Efforts to establish the mechanism by which deregulated E2F1 results in DSBs
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Figure 5.1: Model of cellular tolerance for E2Fl-associated DSBs.
Model represents changes in y H2AX levels in cells relative to the functional status
of the Rb pathway. The tolerated thresholds for wildtype, p53 pathway mutations
and p53 mutations are shown. (Green) In normal cells, any occurrence of E2F1-
associated DSBs wil elicit a p53 response that leads to repair of the damage
apoptosis, or senescence. (Blue) The acute inactivation of the Rb pathway in cells
that are Rb wildtype leads to increased in E2F1-associated yH2AX levels. These
cells wil be selectively pressured to inactivate the p53 pathway in order to avoid
apoptosis or senescence. The inactivation of the p53 pathway raises the threshold
level of tolerated E2F1-associated DSBs; if these cells mutate p53 the threshold
tolerance of E2F I-associated DSBs is further enhanced. Chronic exposure to E2F 
associated DSBs may become detrimental to the cell, and an additional mutation(s)
is incured in order to dampen DSB signaling. (Red) Loss or mutation of Rb results
in derepressed E2F 1 and high levels of DSBs. The elevated levels of E2F 1-
associated DSBs selectively pressures cell to mutate p53 thereby rendering cells
resistant to p53-mediated effects. With time, cells may accumulate a mutation(s) that
reduces E2F I-associated DSB signaling and avoids the deleterious effects of the
breaks.
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have been unfruitful. We know that ROS generation, and by inference, c-MYC activity,
are not involved in the formation of E2F I-associated DSBs. W e also found that MAD2
activity was not required for E2F1-associated yH2AX foci to form. Additionally, we did
not find that E2F1 inhibited topoisomerase II activity (data not shown), despite binding to
the topoisomerase II binding protein, TopBP1 (196). Our findings have also shown that
E2F1-associated DSBs arise independent of functional ATM
, NBS1 , or p53. Therefore
the question stil remains as to how deregulated E2Fl results in DSB accumulation.
One possibility is that E2F 1 may inhibit the timely repair of endogenous DSBs.
Given that the number of y H2AX foci is directly related to the number of DSBs (321) and
that we observe low numbers ofyH2AX foci in cells with deregulated E2F1
, we believe
that this idea is viable. Potentially, E2F1 may localize to the site of an endogenous DSB
and prevent repair factors from binding and/or functioning at the DSB. Consistent with
this idea, phosphorylated E2F1 has been observed at foci following DNA damage (314)
and it has been proposed that E2F 1 interacts with NBS 1 (211), which as par of the MRN
complex, is important for repair signaling. However, we have found that expressing an
E2F1 mutant lacking the published NBS1 binding site, stil results in MREll foci
formation (98) and that E2F I-associated DSBs form independent .of NBS 1 (Figures 3.
and 3. 18).
Another possible mechanism by which deregulated E2F 1 results in DSB
accumulation is that E2F 1 may destabilize replication forks, causing them to stall and
collapse. However, in rodent cells, E2F2 and E2F3a are just as effective at promoting
DNA replication as E2F1 , indicating that some aspect of replication fork dynamics
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activated by E2F1 expression would have to be different than the forks activated by E2F2
or E2F3a expression. Although plausible, the observation that replication fork collapse is
usually signaled by activated ATR and CHK1 (286), which we do not observe in
response to deregulated E2F1 (278), and the observation that deregulated E2F1 can
activate a G checkpoint in human cells (98) suggest this may not be the mechanism.
Furthermore, we did not find a substantial difference in the level of yH2AX foci in
serum-starved or cycling cells expressing E2F1 or E7 (data not shown), suggesting that S
phase progression is not required for the formation of E2F I-associated DSBs.
A final possibility is that deregulated E2F1 may somehow dismantle the well-
organized protection of the ends of linear chromosomes. It is known that in cells with
defective telomeric repeat binding factor 2 protein (TRF2), DNA damage response
proteins like yH2AX, CHK2 and 53BP1 are localized to telomeres (323). However
CHK1 was also found localized to telomeres and we do not see CHK1 activation when
E2F 1 is deregulated (278).
F. Role for E2F! in treatment of genomic instabilty syndromes
Although we do not know how deregulated E2F 1 results in DSBs, it is clear that
E2F1 is post-translationally modified following treatment with DSB agents (139
, 142
192 , 196 255 314). Therefore, E2F1 may be involved in a positive feedback loop where
it plays 11 role in amplifying DSB signaling (268 , 276, 278) by causing additional DSBs
to accumulate. Presumably, in normal cells, or in emerging tumor cells that have retained
a normal E2F 1- induced apoptotic response, this signaling would serve as a safety
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mechanism to initiate apoptosis and ultimately prevent tumor cell formation. However
, in
cells that have a mutated p53 apoptotic/ arrest pathway, these breaks may actually
enhance tumor cell formation.
Because of this potential feedback loop, we believe that there is therapeutic
potential to modulating the level of DSBs in tumor cells by manipulating Rb/E2F 1
activity. In cancer cell lines that retain wildtye like the vast majority of breast
carcinomas, inactivation of Rb may improve the chemotherapeutic or radiation response
by increasing the pool of deregulated E2F1
, and potentially enhancing sensitivity to
apoptosis. Because many of the side-effects of chemotherapy are caused by cell death to
normal cells, the conceivable reduction in dose of the chemotherapeutic agent may be
less toxic to patients. The development of the breast tissue organ cultue system is our
first step in the design of experiments to test whether Rb inactivation and deregulated
E2F 1 protein may cooperate with a genotoxic agent. In the future, excised tumor tissue
and hopefully biopsied tissue, could be examined for levels of yH2AX and E2F1. Using
this information, clinicians would be able to determine the best possible treatment
regimen for individual patients.
The findings in this thesis may also have potential in the treatment of other
genomic instability disorders, like Hutchinson-Gilford Progeria Syndrome (HGPS). Cells
from patients afflicted with HGPS are genomically unstable and have defects in DNA
repair (194). Given that a mutation in Lamin A is responsible for HGPS and that Lamin
A normally functions to protect Rb from proteasomal degradation (152), it is possible that
decreased Rb levels and the resulting deregulation of E2F 1 may be responsible for the
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genomic instability observed in HGPS cells. If tre, then the development of small
molecule inhibitors ofE2F1 may be beneficial for the treatment of these patients.
G. Summary
In summary, the data from this thesis define a novel activity for Rb inactivation
and derepressed E2F , namely the induction of DSB accumulation. This activity is
specific to E2F1 among the activator E2Fs and sheds light on why it is toxic to cells
when deregulated. The potential to modulate levels of DSBs in cells from patients with
cancer or other genomic instability syndromes has important implications in the
development of treatments for these diseases.
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